<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://m2.mtmt.hu/xsl/gui3.xsl" ?>
<myciteResult>
  <serverUrl>https://m2.mtmt.hu/</serverUrl>
  <labelLang>hun</labelLang>
  <responseDate>2026-09-20 16:05</responseDate>
  <content>
    <publication>
      <otype>JournalArticle</otype>
      <mtid>35077353</mtid>
      <status>VALIDATED</status>
      <published>true</published>
      <comment>Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy            
            Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli, 1, Rome, 00168, Italy            
            Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy            
            Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy            
            Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary            
            Pharmahungary Group, Szeged, Hungary            
            MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary            
            HCEMM-SU Cardiometabolic Immunology Research Group, Budapest, Hungary            
            MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Budapest, Hungary            
            Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy            
            University and Fondazione Campus Bio-Medico, Rome, Italy            
            Export Date: 09 June 2026; Cited By: 15; Correspondence Address: M. Camilli; Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy; email: Massimiliano.camilli1@policlinicogemelli.it; CODEN: BRCAB</comment>
      <unhandledTickets>0</unhandledTickets>
      <deleted>false</deleted>
      <lastRefresh>2026-08-10T20:25:26.133+0000</lastRefresh>
      <lastModified>2026-06-09T17:46:02.915+0000</lastModified>
      <created>2024-06-29T17:56:17.071+0000</created>
      <creator>
        <snippet>true</snippet>
        <mtid>10026589</mtid>
        <familyName>Tichy</familyName>
        <givenName>Rita</givenName>
        <link>/api/admin/10026589</link>
        <otype>Admin</otype>
        <label>Tichy Rita (SE_KK_Admin5_TR, admin)</label>
        <published>true</published>
        <oldId>10026589</oldId>
      </creator>
      <lastDuplumSearch>2026-07-07T09:51:06.817+0000</lastDuplumSearch>
      <validated>2025-02-07T10:18:58.075+0000</validated>
      <validator>
        <snippet>true</snippet>
        <mtid>10062250</mtid>
        <familyName>Molnár-Taga</familyName>
        <givenName>Márta</givenName>
        <link>/api/admin/10062250</link>
        <otype>Admin</otype>
        <label>Molnár-Taga Márta (SE 4-es admin)</label>
        <published>true</published>
        <oldId>10062250</oldId>
      </validator>
      <tempLockers>
        <otype>Admin</otype>
        <mtid>10025544</mtid>
        <link>/api/admin/10025544</link>
        <label>Lévayné Deseő Katalin (MTMT Központi admin)</label>
        <familyName>Lévayné Deseő</familyName>
        <givenName>Katalin</givenName>
        <published>true</published>
        <oldId>10025544</oldId>
        <snippet>true</snippet>
      </tempLockers>
      <tempLocked>2026-06-09T18:51:49.136+0000</tempLocked>
      <core>true</core>
      <publicationPending>false</publicationPending>
      <type>
        <snippet>true</snippet>
        <mtid>24</mtid>
        <code>24</code>
        <link>/api/publicationtype/24</link>
        <otype>PublicationType</otype>
        <label>Folyóiratcikk</label>
        <listPosition>1</listPosition>
        <published>true</published>
        <oldId>24</oldId>
        <otypeName>JournalArticle</otypeName>
      </type>
      <subType>
        <snippet>true</snippet>
        <mtid>1134514</mtid>
        <nameEng>Survey paper</nameEng>
        <docType>
          <snippet>true</snippet>
          <mtid>24</mtid>
          <code>24</code>
          <link>/api/publicationtype/24</link>
          <otype>PublicationType</otype>
          <label>Folyóiratcikk</label>
          <listPosition>1</listPosition>
          <published>true</published>
          <oldId>24</oldId>
          <otypeName>JournalArticle</otypeName>
        </docType>
        <link>/api/subtype/1134514</link>
        <name>Összefoglaló cikk</name>
        <otype>SubType</otype>
        <label>Összefoglaló cikk (Folyóiratcikk)</label>
        <listPosition>102</listPosition>
        <published>true</published>
        <oldId>1134514</oldId>
      </subType>
      <category>
        <snippet>true</snippet>
        <mtid>1</mtid>
        <link>/api/category/1</link>
        <otype>Category</otype>
        <label>Tudományos</label>
        <published>true</published>
        <oldId>1</oldId>
      </category>
      <firstAuthor>Camilli, Massimiliano</firstAuthor>
      <title>Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond</title>
      <journal>
        <snippet>true</snippet>
        <sciIndexed>true</sciIndexed>
        <link>/api/journal/656</link>
        <reviewType>REVIEWED</reviewType>
        <label>BASIC RESEARCH IN CARDIOLOGY 0300-8428 1435-1803</label>
        <published>true</published>
        <hungarian>false</hungarian>
        <oldId>656</oldId>
        <noIF>false</noIF>
        <mtid>656</mtid>
        <scopusIndexed>true</scopusIndexed>
        <pIssn>0300-8428</pIssn>
        <eIssn>1435-1803</eIssn>
        <otype>Journal</otype>
        <lang>FOREIGN</lang>
      </journal>
      <volume>120</volume>
      <firstPage>241</firstPage>
      <lastPage>262</lastPage>
      <firstPageOrInternalIdForSort>241</firstPageOrInternalIdForSort>
      <pageLength>22</pageLength>
      <publishedYear>2025</publishedYear>
      <abstractText>Sodium–glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic and direct cardioprotective and nephroprotective effects that extend beyond their glucose-lowering action. These properties prompted their use in two frequently intertwined conditions, heart failure and chronic kidney disease. Their unique mechanism of action makes SGLT2i an attractive option also to lower the rate of cardiac events and improve overall survival of oncological patients with preexisting cardiovascular risk and/or candidate to receive cardiotoxic therapies. This review will cover biological foundations and clinical evidence for SGLT2i modulating myocardial function and metabolism, with a focus on their possible use as cardioprotective agents in the cardio-oncology settings. Furthermore, we will explore recently emerged SGLT2i effects on hematopoiesis and immune system, carrying the potential of attenuating tumor growth and chemotherapy-induced cytopenias.</abstractText>
      <digital>true</digital>
      <printed/>
      <sourceYear>2024</sourceYear>
      <foreignEdition>true</foreignEdition>
      <foreignLanguage>true</foreignLanguage>
      <fullPublication>true</fullPublication>
      <conferencePublication>false</conferencePublication>
      <nationalOrigin>true</nationalOrigin>
      <missingAuthor>false</missingAuthor>
      <oaType>NONE</oaType>
      <oaCheckDate>2026-08-10</oaCheckDate>
      <oaFree>false</oaFree>
      <citationCount>19</citationCount>
      <citationCountUnpublished>0</citationCountUnpublished>
      <citationCountWoOther>19</citationCountWoOther>
      <independentCitCountWoOther>13</independentCitCountWoOther>
      <nationalOriginCitationCount>1</nationalOriginCitationCount>
      <foreignEditionCitationCount>19</foreignEditionCitationCount>
      <doiCitationCount>19</doiCitationCount>
      <wosCitationCount>18</wosCitationCount>
      <scopusCitationCount>15</scopusCitationCount>
      <wosScopusCitationCount>19</wosScopusCitationCount>
      <wosScopusCitationCountWoOther>19</wosScopusCitationCountWoOther>
      <wosScopusIndependentCitationCount>13</wosScopusIndependentCitationCount>
      <wosScopusIndependentCitationCountWoOther>13</wosScopusIndependentCitationCountWoOther>
      <independentCitationCount>13</independentCitationCount>
      <selfCitationCount>6</selfCitationCount>
      <unhandledCitationCount>0</unhandledCitationCount>
      <citingPubCount>19</citingPubCount>
      <independentCitingPubCount>13</independentCitingPubCount>
      <citingPubCountWoOther>19</citingPubCountWoOther>
      <independentCitingPubCountWoOther>13</independentCitingPubCountWoOther>
      <unhandledCitingPubCount>0</unhandledCitingPubCount>
      <citedPubCount>14</citedPubCount>
      <citedCount>14</citedCount>
      <pubStats>
        <types>
          <type>Folyóiratcikk</type>
          <typeEng>Journal Article</typeEng>
          <code>24</code>
          <count>19</count>
        </types>
        <types>
          <type>Könyvrészlet</type>
          <typeEng>Chapter in Book</typeEng>
          <code>25</code>
          <count>0</count>
        </types>
        <types>
          <type>Könyv</type>
          <typeEng>Book</typeEng>
          <code>23</code>
          <count>0</count>
        </types>
        <types>
          <type>Egyéb konferenciaközlemény</type>
          <typeEng>Conference paper</typeEng>
          <code>31</code>
          <count>0</count>
        </types>
        <types>
          <type>Egyéb konferenciakötet</type>
          <typeEng>Conference proceedings</typeEng>
          <code>32</code>
          <count>0</count>
        </types>
        <types>
          <type>Oltalmi formák</type>
          <typeEng>Protection forms</typeEng>
          <code>26</code>
          <count>0</count>
        </types>
        <types>
          <type>Disszertáció</type>
          <typeEng>Thesis</typeEng>
          <code>28</code>
          <count>0</count>
        </types>
        <types>
          <type>Egyéb</type>
          <typeEng>Miscellaneous</typeEng>
          <code>29</code>
          <count>0</count>
        </types>
        <types>
          <type>Alkotás</type>
          <typeEng>Achievement</typeEng>
          <code>22</code>
          <count>0</count>
        </types>
        <types>
          <type>Kutatási adat</type>
          <typeEng>Research data</typeEng>
          <code>33</code>
          <count>0</count>
        </types>
        <citationTypes>
          <type>Folyóiratcikk</type>
          <typeEng>Journal Article</typeEng>
          <code>24</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Könyvrészlet</type>
          <typeEng>Chapter in Book</typeEng>
          <code>25</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Könyv</type>
          <typeEng>Book</typeEng>
          <code>23</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb konferenciaközlemény</type>
          <typeEng>Conference paper</typeEng>
          <code>31</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb konferenciakötet</type>
          <typeEng>Conference proceedings</typeEng>
          <code>32</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Oltalmi formák</type>
          <typeEng>Protection forms</typeEng>
          <code>26</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Disszertáció</type>
          <typeEng>Thesis</typeEng>
          <code>28</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb</type>
          <typeEng>Miscellaneous</typeEng>
          <code>29</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Alkotás</type>
          <typeEng>Achievement</typeEng>
          <code>22</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Kutatási adat</type>
          <typeEng>Research data</typeEng>
          <code>33</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <years>
          <year>2024</year>
          <publicationCount>0</publicationCount>
          <citationCount>2</citationCount>
          <independentCitationCount>0</independentCitationCount>
          <citingPubCount>2</citingPubCount>
          <independentCitingPubCount>0</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
        <years>
          <year>2025</year>
          <publicationCount>0</publicationCount>
          <citationCount>10</citationCount>
          <independentCitationCount>8</independentCitationCount>
          <citingPubCount>10</citingPubCount>
          <independentCitingPubCount>8</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
        <years>
          <year>2026</year>
          <publicationCount>0</publicationCount>
          <citationCount>7</citationCount>
          <independentCitationCount>5</independentCitationCount>
          <citingPubCount>7</citingPubCount>
          <independentCitingPubCount>5</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
      </pubStats>
      <ratingsForSort>D1</ratingsForSort>
      <hasCitationDuplums>false</hasCitationDuplums>
      <importDuplum>false</importDuplum>
      <importOverwritten>false</importOverwritten>
      <importSkipped>false</importSkipped>
      <userChangeableUntil>2024-09-27T17:57:02.158+0000</userChangeableUntil>
      <directInstitutesForSort>Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI); MTA-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI)</directInstitutesForSort>
      <ownerAuthorCount>2</ownerAuthorCount>
      <ownerInstituteCount>19</ownerInstituteCount>
      <directInstituteCount>4</directInstituteCount>
      <authorCount>16</authorCount>
      <contributorCount>0</contributorCount>
      <hasQualityFactor>true</hasQualityFactor>
      <tempLockerIds>10025544</tempLockerIds>
      <languages>
        <language>
          <otype>Language</otype>
          <mtid>10002</mtid>
          <link>/api/language/10002</link>
          <label>Angol</label>
          <name>Angol</name>
          <nameEng>English</nameEng>
          <published>true</published>
          <oldId>2</oldId>
          <snippet>true</snippet>
        </language>
      </languages>
      <authorships>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090059</mtid>
          <link>/api/authorship/118090059</link>
          <label>Camilli, Massimiliano ✉</label>
          <listPosition>1</listPosition>
          <share>0.063</share>
          <first>true</first>
          <last>false</last>
          <corresponding>true</corresponding>
          <familyName>Camilli</familyName>
          <givenName>Massimiliano</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090060</mtid>
          <link>/api/authorship/118090060</link>
          <label>Viscovo, Marcello*</label>
          <listPosition>2</listPosition>
          <share>0.063</share>
          <first>true</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Viscovo</familyName>
          <givenName>Marcello</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090061</mtid>
          <link>/api/authorship/118090061</link>
          <label>Maggio, Luca*</label>
          <listPosition>3</listPosition>
          <share>0.063</share>
          <first>true</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Maggio</familyName>
          <givenName>Luca</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090062</mtid>
          <link>/api/authorship/118090062</link>
          <label>Bonanni, Alice</label>
          <listPosition>4</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Bonanni</familyName>
          <givenName>Alice</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090063</mtid>
          <link>/api/authorship/118090063</link>
          <label>Torre, Ilaria</label>
          <listPosition>5</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Torre</familyName>
          <givenName>Ilaria</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090064</mtid>
          <link>/api/authorship/118090064</link>
          <label>Pellegrino, Claudio</label>
          <listPosition>6</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Pellegrino</familyName>
          <givenName>Claudio</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090065</mtid>
          <link>/api/authorship/118090065</link>
          <label>Lamendola, Priscilla</label>
          <listPosition>7</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Lamendola</familyName>
          <givenName>Priscilla</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090066</mtid>
          <link>/api/authorship/118090066</link>
          <label>Tinti, Lorenzo</label>
          <listPosition>8</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Tinti</familyName>
          <givenName>Lorenzo</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090067</mtid>
          <link>/api/authorship/118090067</link>
          <label>Teofili, Luciana</label>
          <listPosition>9</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Teofili</familyName>
          <givenName>Luciana</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090068</mtid>
          <link>/api/authorship/118090068</link>
          <label>Hohaus, Stefan</label>
          <listPosition>10</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Hohaus</familyName>
          <givenName>Stefan</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090069</mtid>
          <link>/api/authorship/118090069</link>
          <label>Lanza, Gaetano Antonio</label>
          <listPosition>11</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Lanza</familyName>
          <givenName>Gaetano Antonio</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090070</mtid>
          <link>/api/authorship/118090070</link>
          <label>Ferdinandy, Peter [Ferdinandy, Péter (Farmakológia, mol...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); MTA-SE Rendszerfarmakológiai Kutatócsoport (SE / AOK / I / FFI)</label>
          <listPosition>12</listPosition>
          <share>0.063</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <author>
            <otype>Author</otype>
            <mtid>10010125</mtid>
            <link>/api/author/10010125</link>
            <label>Ferdinandy Péter (Farmakológia, molekuláris medicina)</label>
            <familyName>Ferdinandy</familyName>
            <givenName>Péter</givenName>
            <published>true</published>
            <oldId>10010125</oldId>
            <snippet>true</snippet>
          </author>
          <familyName>Ferdinandy</familyName>
          <givenName>Peter</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090071</mtid>
          <link>/api/authorship/118090071</link>
          <label>Varga, Zoltan [Varga, Zoltán (kardiovaszkuláris...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); HCEMM-SE Kardiometabolikus Immunológia Kutatócs... (SE / AOK / I / FFI); MTA-SE Momentum Kardio-Onkológia és Kardioimmun... (SE / AOK / I / FFI)</label>
          <listPosition>13</listPosition>
          <share>0.063</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <author>
            <otype>Author</otype>
            <mtid>10028393</mtid>
            <link>/api/author/10028393</link>
            <label>Varga Zoltán (kardiovaszkuláris kutatás)</label>
            <familyName>Varga</familyName>
            <givenName>Zoltán</givenName>
            <published>true</published>
            <oldId>10028393</oldId>
            <snippet>true</snippet>
          </author>
          <familyName>Varga</familyName>
          <givenName>Zoltan</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090072</mtid>
          <link>/api/authorship/118090072</link>
          <label>Crea, Filippo</label>
          <listPosition>14</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Crea</familyName>
          <givenName>Filippo</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090073</mtid>
          <link>/api/authorship/118090073</link>
          <label>Lombardo, Antonella</label>
          <listPosition>15</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <familyName>Lombardo</familyName>
          <givenName>Antonella</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>118090074</mtid>
          <link>/api/authorship/118090074</link>
          <label>Minotti, Giorgio</label>
          <listPosition>16</listPosition>
          <share>0.0625</share>
          <first>false</first>
          <last>true</last>
          <corresponding>false</corresponding>
          <familyName>Minotti</familyName>
          <givenName>Giorgio</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
      </authorships>
      <identifiers>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>26743154</mtid>
          <link>/api/publicationidentifier/26743154</link>
          <label>DOI: 10.1007/s00395-024-01059-9</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>6</mtid>
            <link>/api/publicationsource/6</link>
            <label>DOI</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10001</mtid>
              <link>/api/publicationsourcetype/10001</link>
              <label>DOI</label>
              <mayHaveOa>true</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>DOI</name>
            <nameEng>DOI</nameEng>
            <linkPattern>https://doi.org/@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>6</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>10.1007/s00395-024-01059-9</idValue>
          <realUrl>https://doi.org/10.1007/s00395-024-01059-9</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>26814611</mtid>
          <link>/api/publicationidentifier/26814611</link>
          <label>WoS: 001256980900001</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>1</mtid>
            <link>/api/publicationsource/1</link>
            <label>WoS</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>WoS</name>
            <nameEng>WoS</nameEng>
            <linkPattern>https://www.webofscience.com/wos/woscc/full-record/@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>1</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>001256980900001</idValue>
          <realUrl>https://www.webofscience.com/wos/woscc/full-record/001256980900001</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>26815031</mtid>
          <link>/api/publicationidentifier/26815031</link>
          <label>Scopus: 85197457276</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>3</mtid>
            <link>/api/publicationsource/3</link>
            <label>Scopus</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>Scopus</name>
            <nameEng>Scopus</nameEng>
            <linkPattern>http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>3</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>85197457276</idValue>
          <realUrl>http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85197457276</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>26743155</mtid>
          <link>/api/publicationidentifier/26743155</link>
          <label>PubMed: 38935171</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>17</mtid>
            <link>/api/publicationsource/17</link>
            <label>PubMed</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>PubMed</name>
            <nameEng>PubMed</nameEng>
            <linkPattern>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=@@@&amp;dopt=Abstract</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>17</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>38935171</idValue>
          <realUrl>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=38935171&amp;dopt=Abstract</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>31185751</mtid>
          <link>/api/publicationidentifier/31185751</link>
          <label>Egyéb URL: https://link.springer.com/10.1007/s00395-024-01059-9</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>40</mtid>
            <link>/api/publicationsource/40</link>
            <label>Egyéb URL</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10006</mtid>
              <link>/api/publicationsourcetype/10006</link>
              <label>Link</label>
              <mayHaveOa>true</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>Egyéb URL</name>
            <nameEng>Other URL</nameEng>
            <linkPattern>@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>40</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>https://link.springer.com/10.1007/s00395-024-01059-9</idValue>
          <realUrl>https://link.springer.com/10.1007/s00395-024-01059-9</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>31872582</mtid>
          <link>/api/publicationidentifier/31872582</link>
          <label>Egyéb URL: https://www.scopus.com/pages/publications/85197457276?origin=resultslist</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>40</mtid>
            <link>/api/publicationsource/40</link>
            <label>Egyéb URL</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10006</mtid>
              <link>/api/publicationsourcetype/10006</link>
              <label>Link</label>
              <mayHaveOa>true</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>Egyéb URL</name>
            <nameEng>Other URL</nameEng>
            <linkPattern>@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>40</oldId>
            <snippet>true</snippet>
          </source>
          <oaType>NONE</oaType>
          <validState>IDENTICAL</validState>
          <idValue>https://www.scopus.com/pages/publications/85197457276?origin=resultslist</idValue>
          <realUrl>https://www.scopus.com/pages/publications/85197457276?origin=resultslist</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
      </identifiers>
      <ratings>
        <rating>
          <otype>SjrRating</otype>
          <mtid>11563276</mtid>
          <link>/api/sjrrating/11563276</link>
          <label>sjr:D1 (2025) Scopus - Cardiology and Cardiovascular Medicine BASIC RESEARCH IN CARDIOLOGY 0300-8428 1435-1803</label>
          <listPos>20</listPos>
          <rankValue>0.1</rankValue>
          <type>journal</type>
          <ratingType>
            <otype>RatingType</otype>
            <mtid>10002</mtid>
            <link>/api/ratingtype/10002</link>
            <label>sjr</label>
            <code>sjr</code>
            <published>true</published>
            <snippet>true</snippet>
          </ratingType>
          <subject>
            <otype>ClassificationExternal</otype>
            <mtid>2705</mtid>
            <link>/api/classificationexternal/2705</link>
            <label>Scopus - Cardiology and Cardiovascular Medicine</label>
            <published>true</published>
            <oldId>2705</oldId>
            <snippet>true</snippet>
          </subject>
          <ranking>D1</ranking>
          <calculation>DIRECT</calculation>
          <published>true</published>
          <snippet>true</snippet>
        </rating>
      </ratings>
      <references>
        <reference>
          <otype>Reference</otype>
          <mtid>55283294</mtid>
          <link>/api/reference/55283294</link>
          <label>1. Abdel-Qadir H, Carrasco R, Austin PC, Chen Y, Zhou L, Fang J, Su HMH, Lega IC, Kaul P, Neilan TG, Thavendiranathan P (2023) The association of sodium–glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC CardioOncol 5:318–328. https://doi.org/10.1016/J.JACCAO.2023.03.011, DOI: 10.1016/J.JACCAO.2023.03.011</label>
          <listPosition>1</listPosition>
          <doi>10.1016/J.JACCAO.2023.03.011</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283295</mtid>
          <link>/api/reference/55283295</link>
          <label>2. Abdel-Razeq H, Hashem H (2020) Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol. https://doi.org/10.1016/J.CRITREVONC.2019.102837, DOI: 10.1016/J.CRITREVONC.2019.102837</label>
          <listPosition>2</listPosition>
          <doi>10.1016/J.CRITREVONC.2019.102837</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283296</mtid>
          <link>/api/reference/55283296</link>
          <label>3. Abu-Qaoud MR, Kumar A, Tarun T, Abraham S, Ahmad J, Khadke S, Husami R, Kulbak G, Sahoo S, Januzzi JL, Neilan TG, Baron SJ, Martin D, Nohria A, Reynolds MR, Kosiborod M, Dani SS, Ganatra S (2023) Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol 9:2109–2118. https://doi.org/10.1016/J.JACEP.2023.06.008, DOI: 10.1016/J.JACEP.2023.06.008</label>
          <listPosition>3</listPosition>
          <doi>10.1016/J.JACEP.2023.06.008</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283297</mtid>
          <link>/api/reference/55283297</link>
          <label>4. Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. https://doi.org/10.1186/S13045-019-0779-5, DOI: 10.1186/S13045-019-0779-5</label>
          <listPosition>4</listPosition>
          <doi>10.1186/S13045-019-0779-5</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283298</mtid>
          <link>/api/reference/55283298</link>
          <label>5. Albiero M, Tedesco S, Amendolagine FI, D’anna M, Migliozzi L, Zuccolotto G, Rosato A, Cappellari R, Avogaro A, Fadini GP (2021) Inhibition of SGLT2 rescues bone marrow cell traffic for vascular repair: role of glucose control and ketogenesis. Diabetes 70:1767–1779. https://doi.org/10.2337/DB20-1045, DOI: 10.2337/DB20-1045</label>
          <listPosition>5</listPosition>
          <doi>10.2337/DB20-1045</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283299</mtid>
          <link>/api/reference/55283299</link>
          <label>6. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461. https://doi.org/10.1056/NEJMOA2107038/SUPPL_FILE/NEJMOA2107038_DATA-SHARING.PDF, DOI: 10.1056/NEJMOA2107038/SUPPL_FILE/NEJMOA2107038_DATA-SHARING.PDF</label>
          <listPosition>6</listPosition>
          <doi>10.1056/NEJMOA2107038/SUPPL_FILE/NEJMOA2107038_DATA-SHARING.PDF</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283300</mtid>
          <link>/api/reference/55283300</link>
          <label>7. Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, De Boer RA, Ghigo A, Grumbach IM, Jain S, Zhu H (2021) Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association. Circ Res 129:E21–E34. https://doi.org/10.1161/RES.0000000000000473, DOI: 10.1161/RES.0000000000000473</label>
          <listPosition>7</listPosition>
          <doi>10.1161/RES.0000000000000473</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283301</mtid>
          <link>/api/reference/55283301</link>
          <label>8. Association AD (2021) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care 44:S111–S124. https://doi.org/10.2337/DC21-S009, DOI: 10.2337/DC21-S009</label>
          <listPosition>8</listPosition>
          <doi>10.2337/DC21-S009</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283302</mtid>
          <link>/api/reference/55283302</link>
          <label>9. Atkins MB, Tannir NM (2018) Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev 70:127–137. https://doi.org/10.1016/J.CTRV.2018.07.009, DOI: 10.1016/J.CTRV.2018.07.009</label>
          <listPosition>9</listPosition>
          <doi>10.1016/J.CTRV.2018.07.009</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283303</mtid>
          <link>/api/reference/55283303</link>
          <label>10. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP (2016) The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation 133:698–705. https://doi.org/10.1161/CIRCULATIONAHA.115.017355, DOI: 10.1161/CIRCULATIONAHA.115.017355</label>
          <listPosition>10</listPosition>
          <doi>10.1161/CIRCULATIONAHA.115.017355</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283304</mtid>
          <link>/api/reference/55283304</link>
          <label>11. Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang EH, Ky B, Lenihan D, Nohria A, Dani SS, Ganatra S (2023) SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. https://doi.org/10.1016/J.JCHF.2023.08.026, DOI: 10.1016/J.JCHF.2023.08.026</label>
          <listPosition>11</listPosition>
          <doi>10.1016/J.JCHF.2023.08.026</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283305</mtid>
          <link>/api/reference/55283305</link>
          <label>12. Ay C, Grilz E, Nopp S, Moik F, Königsbrügge O, Klimek P, Thurner S, Posch F, Pabinger I (2022) Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study. Res Pract Thromb Haemost 7. https://doi.org/10.1016/J.RPTH.2022.100026, DOI: 10.1016/J.RPTH.2022.100026</label>
          <listPosition>12</listPosition>
          <doi>10.1016/J.RPTH.2022.100026</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283306</mtid>
          <link>/api/reference/55283306</link>
          <label>13. Bernard Z, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broed UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:17–18. https://doi.org/10.1056/NEJMOA1504720, DOI: 10.1056/NEJMOA1504720</label>
          <listPosition>13</listPosition>
          <doi>10.1056/NEJMOA1504720</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283307</mtid>
          <link>/api/reference/55283307</link>
          <label>14. Baartscheer A, Schumacher CA, Wüst RCI, Fiolet JWT, Stienen GJM, Coronel R, Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60:568–573. https://doi.org/10.1007/S00125-016-4134-X/FIGURES/2, DOI: 10.1007/S00125-016-4134-X/FIGURES/2</label>
          <listPosition>14</listPosition>
          <doi>10.1007/S00125-016-4134-X/FIGURES/2</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283308</mtid>
          <link>/api/reference/55283308</link>
          <label>15. Bhagat A, Shrestha P, Kleinerman ES (2022) The Innate Immune System in Cardiovascular Diseases and Its Role in Doxorubicin-Induced Cardiotoxicity. Int J Mol Sci 23. https://doi.org/10.3390/IJMS232314649, DOI: 10.3390/IJMS232314649</label>
          <listPosition>15</listPosition>
          <doi>10.3390/IJMS232314649</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283309</mtid>
          <link>/api/reference/55283309</link>
          <label>16. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifiro G, Yang H, Lazo-Langner A (2019) Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv 3:1197–1210. https://doi.org/10.1182/BLOODADVANCES.2018030387, DOI: 10.1182/BLOODADVANCES.2018030387</label>
          <listPosition>16</listPosition>
          <doi>10.1182/BLOODADVANCES.2018030387</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283310</mtid>
          <link>/api/reference/55283310</link>
          <label>17. Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 44:457–464. https://doi.org/10.1016/J.DIABET.2018.09.005, DOI: 10.1016/J.DIABET.2018.09.005</label>
          <listPosition>17</listPosition>
          <doi>10.1016/J.DIABET.2018.09.005</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283311</mtid>
          <link>/api/reference/55283311</link>
          <label>18. Bouleftour W, Mery B, Rowinski E, Rivier C, Daguenet E, Magne N (2021) Cardio-Oncology Preclinical Models: A Comprehensive Review. Anticancer Res 41:5355–5364. https://doi.org/10.21873/ANTICANRES.15348, DOI: 10.21873/ANTICANRES.15348</label>
          <listPosition>18</listPosition>
          <doi>10.21873/ANTICANRES.15348</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283312</mtid>
          <link>/api/reference/55283312</link>
          <label>19. Camilli M, Lombardi M, Chiabrando JG, Del Buono MG, Montone RA, Biondi-Zoccai G, Crea F, Minotti G (2021) Efficacy of sodium–glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis. Eur Heart J Cardiovasc Pharmacother 7:E74–E76. https://doi.org/10.1093/EHJCVP/PVAB034, DOI: 10.1093/EHJCVP/PVAB034</label>
          <listPosition>19</listPosition>
          <doi>10.1093/EHJCVP/PVAB034</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283313</mtid>
          <link>/api/reference/55283313</link>
          <label>20. Camilli M, Lombardi M, Chiabrando JG, Zito A, Del Buono MG, Vergallo R, Aspromonte N, Lombardo A, Montone RA, Niccoli G, Biondi-Zoccai G, Crea F, Minotti G (2022) Sodium–glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients with Heart Failure: Evidence from a Meta-Analysis of Randomized Trials. Am J Ther 29:E199–E204. https://doi.org/10.1097/MJT.0000000000001452, DOI: 10.1097/MJT.0000000000001452</label>
          <listPosition>20</listPosition>
          <doi>10.1097/MJT.0000000000001452</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283314</mtid>
          <link>/api/reference/55283314</link>
          <label>21. Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt ET, Thuresson M, Fenici P, Hammar N, Kosiborod M, Holl RW, Chen H, Scheerer MF, Surmont F, Nahrebne K, Gulseth HL, Carstensen B, Bollow E, García Rodríguez LA, Cea Soriano L, Cantero OF, Thiel E, Murphy B (2018) SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol 71:2497–2506. https://doi.org/10.1016/J.JACC.2018.01.085, DOI: 10.1016/J.JACC.2018.01.085</label>
          <listPosition>21</listPosition>
          <doi>10.1016/J.JACC.2018.01.085</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283315</mtid>
          <link>/api/reference/55283315</link>
          <label>22. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Therapy 1:57–92. https://doi.org/10.1007/S13300-010-0006-4/FIGURES/28, DOI: 10.1007/S13300-010-0006-4/FIGURES/28</label>
          <listPosition>22</listPosition>
          <doi>10.1007/S13300-010-0006-4/FIGURES/28</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283316</mtid>
          <link>/api/reference/55283316</link>
          <label>23. Cheng WL, Kao YH, Chen SA, Chen YJ (2016) Pathophysiology of cancer therapy-provoked atrial fibrillation. Int J Cardiol 219:186–194. https://doi.org/10.1016/J.IJCARD.2016.06.009, DOI: 10.1016/J.IJCARD.2016.06.009</label>
          <listPosition>23</listPosition>
          <doi>10.1016/J.IJCARD.2016.06.009</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283317</mtid>
          <link>/api/reference/55283317</link>
          <label>24. Chiang CH, Chiang CH, Chiang CH, Ma KSK, Peng CY, Hsia YP, Horng CS, Chen CY, Chang YC, See XY, Chen YJ, Wang SS, Suero-Abreu GA, Peterson LR, Thavendiranathan P, Armand P, Peng CM, Shiah HS, Neilan TG (2023) Impact of sodium–glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart 109:470–477. https://doi.org/10.1136/HEARTJNL-2022-321545, DOI: 10.1136/HEARTJNL-2022-321545</label>
          <listPosition>24</listPosition>
          <doi>10.1136/HEARTJNL-2022-321545</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283318</mtid>
          <link>/api/reference/55283318</link>
          <label>25. Cowie MR, Fisher M (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 17:761–772. https://doi.org/10.1038/S41569-020-0406-8, DOI: 10.1038/S41569-020-0406-8</label>
          <listPosition>25</listPosition>
          <doi>10.1038/S41569-020-0406-8</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283319</mtid>
          <link>/api/reference/55283319</link>
          <label>26. Dabour MS, Abdelgawad IY, Grant MKO, El-Sawaf ES, Zordoky BN (2023) Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway. Biomed Pharmacother 164:114907. https://doi.org/10.1016/J.BIOPHA.2023.114907, DOI: 10.1016/J.BIOPHA.2023.114907</label>
          <listPosition>26</listPosition>
          <doi>10.1016/J.BIOPHA.2023.114907</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283320</mtid>
          <link>/api/reference/55283320</link>
          <label>27. Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, Xu Y, Feng J, Yuan M, Gao X, Wang J, Xu X, Li S, Wu H, Cao J, He Q, Yang B (2023) Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Invest. https://doi.org/10.1172/JCI154754, DOI: 10.1172/JCI154754</label>
          <listPosition>27</listPosition>
          <doi>10.1172/JCI154754</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283321</mtid>
          <link>/api/reference/55283321</link>
          <label>28. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA (2009) Regulation of Hypoxia-Inducible Factor 2α Signaling by the Stress-Responsive Deacetylase Sirtuin 1. Science (1979) 324:1289–1293. https://doi.org/10.1126/SCIENCE.1169956/SUPPL_FILE/DIOUM_SOM.PDF, DOI: 10.1126/SCIENCE.1169956/SUPPL_FILE/DIOUM_SOM.PDF</label>
          <listPosition>28</listPosition>
          <doi>10.1126/SCIENCE.1169956/SUPPL_FILE/DIOUM_SOM.PDF</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283322</mtid>
          <link>/api/reference/55283322</link>
          <label>29. Dutka M, Bobiński R, Francuz T, Garczorz W, Zimmer K, Ilczak T, Ćwiertnia M, Hajduga MB (2022) SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives. Cancers (Basel). https://doi.org/10.3390/CANCERS14235811, DOI: 10.3390/CANCERS14235811</label>
          <listPosition>29</listPosition>
          <doi>10.3390/CANCERS14235811</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283323</mtid>
          <link>/api/reference/55283323</link>
          <label>30. Ekanayake P, Mudaliar S (2023) Increase in hematocrit with SGLT-2 inhibitors—hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia? Diabetes Metab Syndr. https://doi.org/10.1016/J.DSX.2022.102702, DOI: 10.1016/J.DSX.2022.102702</label>
          <listPosition>30</listPosition>
          <doi>10.1016/J.DSX.2022.102702</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283324</mtid>
          <link>/api/reference/55283324</link>
          <label>31. Faggiano A, Gherbesi E, Cardinale D, Vicenzi M, Carugo S (2023) SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: a systematic-review and meta-analysis. Vascul Pharmacol 150:107171. https://doi.org/10.1016/j.vph.2023.107171, DOI: 10.1016/j.vph.2023.107171</label>
          <listPosition>31</listPosition>
          <doi>10.1016/j.vph.2023.107171</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283325</mtid>
          <link>/api/reference/55283325</link>
          <label>32. Fang X, Ardehali H, Min J, Wang F (2023) The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol 20:7–23. https://doi.org/10.1038/S41569-022-00735-4, DOI: 10.1038/S41569-022-00735-4</label>
          <listPosition>32</listPosition>
          <doi>10.1038/S41569-022-00735-4</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283326</mtid>
          <link>/api/reference/55283326</link>
          <label>33. Farkouh ME, Verma S (2018) Prevention of heart failure with SGLT-2 inhibition: insights from CVD-real. J Am Coll Cardiol 71:2507–2510. https://doi.org/10.1016/J.JACC.2018.02.078, DOI: 10.1016/J.JACC.2018.02.078</label>
          <listPosition>33</listPosition>
          <doi>10.1016/J.JACC.2018.02.078</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283327</mtid>
          <link>/api/reference/55283327</link>
          <label>34. Farmakis D, Filippatos G (2021) Arrhythmias in cancer: rhythm is gonna get you! Eur J Heart Fail 23:154–156. https://doi.org/10.1002/EJHF.2079, DOI: 10.1002/EJHF.2079</label>
          <listPosition>34</listPosition>
          <doi>10.1002/EJHF.2079</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283328</mtid>
          <link>/api/reference/55283328</link>
          <label>35. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242. https://doi.org/10.1111/J.1600-065X.2010.00923.X, DOI: 10.1111/J.1600-065X.2010.00923.X</label>
          <listPosition>35</listPosition>
          <doi>10.1111/J.1600-065X.2010.00923.X</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283329</mtid>
          <link>/api/reference/55283329</link>
          <label>36. Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, Basavarajappa D, Rådmark O, Kobayashi S, Seibt T, Beck H, Neff F, Esposito I, Wanke R, Förster H, Yefremova O, Heinrichmeyer M, Bornkamm GW, Geissler EK, Thomas SB, Stockwell BR, Odonnell VB, Kagan VE, Schick JA, Conrad M (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16(12):1180–1191. https://doi.org/10.1038/ncb3064, DOI: 10.1038/ncb3064</label>
          <listPosition>36</listPosition>
          <doi>10.1038/ncb3064</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283330</mtid>
          <link>/api/reference/55283330</link>
          <label>37. Fuchs Andersen C, Omar M, Glenthøj A, El Fassi D, Møller HJ, Lindholm Kurtzhals JA, Styrishave B, Kistorp C, Tuxen C, Poulsen MK, Faber J, Køber L, Gustafsson F, Møller JE, Schou M, Jensen J (2023) Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail 25:226–234. https://doi.org/10.1002/EJHF.2735, DOI: 10.1002/EJHF.2735</label>
          <listPosition>37</listPosition>
          <doi>10.1002/EJHF.2735</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283331</mtid>
          <link>/api/reference/55283331</link>
          <label>38. Fujiwara M, Shimizu M, Okano T, Maejima Y, Shimomura K (2023) Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium–glucose transporter 2 inhibitor: a case report and systematic review. Front Public Health. https://doi.org/10.3389/FPUBH.2023.1264056, DOI: 10.3389/FPUBH.2023.1264056</label>
          <listPosition>38</listPosition>
          <doi>10.3389/FPUBH.2023.1264056</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283332</mtid>
          <link>/api/reference/55283332</link>
          <label>39. Gambardella J, Santulli G, Fiordelisi A, Cerasuolo FA, Wang X, Prevete N, Sommella E, Avvisato R, Buonaiuto A, Altobelli GG, Rinaldi L, Chiuso F, Feliciello A, Dal Piaz F, Campiglia P, Ciccarelli M, Morisco C, Sadoshima J, Iaccarino G, Sorriento D (2023) Infiltrating macrophages amplify doxorubicin-induced cardiac damage: role of catecholamines. Cell Mol Life Sci 80:1–14. https://doi.org/10.1007/S00018-023-04922-5/FIGURES/6, DOI: 10.1007/S00018-023-04922-5/FIGURES/6</label>
          <listPosition>39</listPosition>
          <doi>10.1007/S00018-023-04922-5/FIGURES/6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283333</mtid>
          <link>/api/reference/55283333</link>
          <label>40. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF (2013) Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res 33:13–20</label>
          <listPosition>40</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283334</mtid>
          <link>/api/reference/55283334</link>
          <label>41. Gangat N, Abdallah M, Szuber N, Saliba A, Alkhateeb H, Al-Kali A, Begna KH, Pardanani A, Tefferi A (2023) Sodium–glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. Am J Hematol. https://doi.org/10.1002/AJH.26933, DOI: 10.1002/AJH.26933</label>
          <listPosition>41</listPosition>
          <doi>10.1002/AJH.26933</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283335</mtid>
          <link>/api/reference/55283335</link>
          <label>42. Gangat N, Szuber N, Alkhateeb H, Al-Kali A, Pardanani A, Tefferi A (2021) JAK2 wild-type erythrocytosis associated with sodium–glucose cotransporter 2 inhibitor therapy. Blood 138:2886–2889. https://doi.org/10.1182/BLOOD.2021013996, DOI: 10.1182/BLOOD.2021013996</label>
          <listPosition>42</listPosition>
          <doi>10.1182/BLOOD.2021013996</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283336</mtid>
          <link>/api/reference/55283336</link>
          <label>43. Gao J, Xue G, Zhan G, Wang X, Li J, Yang X, Xia Y (2022) Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med. https://doi.org/10.3389/FCVM.2022.1011429, DOI: 10.3389/FCVM.2022.1011429</label>
          <listPosition>43</listPosition>
          <doi>10.3389/FCVM.2022.1011429</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283337</mtid>
          <link>/api/reference/55283337</link>
          <label>44. Gao M, Monian P, Quadri N, Ramasamy R, Jiang X (2015) Glutaminolysis and transferrin regulate ferroptosis. Mol Cell 59:298–308. https://doi.org/10.1016/j.molcel.2015.06.011, DOI: 10.1016/j.molcel.2015.06.011</label>
          <listPosition>44</listPosition>
          <doi>10.1016/j.molcel.2015.06.011</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283338</mtid>
          <link>/api/reference/55283338</link>
          <label>45. Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, Chaudhuri A, Dandona P (2020) Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab 105:e1056–e1063. https://doi.org/10.1210/CLINEM/DGAA057, DOI: 10.1210/CLINEM/DGAA057</label>
          <listPosition>45</listPosition>
          <doi>10.1210/CLINEM/DGAA057</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283339</mtid>
          <link>/api/reference/55283339</link>
          <label>46. Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG (2022) Sodium–glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail 10:559–567. https://doi.org/10.1016/J.JCHF.2022.03.006, DOI: 10.1016/J.JCHF.2022.03.006</label>
          <listPosition>46</listPosition>
          <doi>10.1016/J.JCHF.2022.03.006</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283340</mtid>
          <link>/api/reference/55283340</link>
          <label>47. Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG (2017) Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 16:1–15. https://doi.org/10.1186/S12933-016-0489-Z/FIGURES/7, DOI: 10.1186/S12933-016-0489-Z/FIGURES/7</label>
          <listPosition>47</listPosition>
          <doi>10.1186/S12933-016-0489-Z/FIGURES/7</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283341</mtid>
          <link>/api/reference/55283341</link>
          <label>48. Hajjar LA, Fonseca SMR, Machado TIV (2021) Atrial fibrillation and cancer. Front Cardiovasc Med. https://doi.org/10.3389/FCVM.2021.590768, DOI: 10.3389/FCVM.2021.590768</label>
          <listPosition>48</listPosition>
          <doi>10.3389/FCVM.2021.590768</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283342</mtid>
          <link>/api/reference/55283342</link>
          <label>49. Han Y, Liu D, Li L (2020) PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10:727–742</label>
          <listPosition>49</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283343</mtid>
          <link>/api/reference/55283343</link>
          <label>50. Hendryx M, Dong Y, Ndeke JM, Luo J (2022) Sodium–glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. PLoS ONE. https://doi.org/10.1371/JOURNAL.PONE.0274519, DOI: 10.1371/JOURNAL.PONE.0274519</label>
          <listPosition>50</listPosition>
          <doi>10.1371/JOURNAL.PONE.0274519</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283344</mtid>
          <link>/api/reference/55283344</link>
          <label>51. Hess DA, Terenzi DC, Trac JZ, Quan A, Mason T, Al-Omran M, Bhatt DL, Dhingra N, Rotstein OD, Leiter LA, Zinman B, Sabongui S, Yan AT, Teoh H, Mazer CD, Connelly KA, Verma S (2019) SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab 30:609–613. https://doi.org/10.1016/J.CMET.2019.08.015, DOI: 10.1016/J.CMET.2019.08.015</label>
          <listPosition>51</listPosition>
          <doi>10.1016/J.CMET.2019.08.015</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283345</mtid>
          <link>/api/reference/55283345</link>
          <label>52. Heusch G (2023) Cardioprotection in cardio-oncology: a case for concern? Cardiovasc Res 119:e144–e145. https://doi.org/10.1093/cvr/cvad111, DOI: 10.1093/cvr/cvad111</label>
          <listPosition>52</listPosition>
          <doi>10.1093/cvr/cvad111</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283346</mtid>
          <link>/api/reference/55283346</link>
          <label>53. Heusch G (2024) Myocardial ischemia/reperfusion: translational pathophysiology of ischemic heart disease. Med (N Y) 5:10–31. https://doi.org/10.1016/j.medj.2023.12.007, DOI: 10.1016/j.medj.2023.12.007</label>
          <listPosition>53</listPosition>
          <doi>10.1016/j.medj.2023.12.007</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283347</mtid>
          <link>/api/reference/55283347</link>
          <label>54. Heusch G, Andreadou I, Bell R, Bertero E, Botker H-E, Davidson SM, Downey J, Eaton P, Ferdinandy P, Gersh BJ, Giacca M, Hausenloy DJ, Ibanez B, Krieg T, Maack C, Schulz R, Sellke F, Shah AM, Thiele H, Yellon DM, Di Lisa F (2023) Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection. Redox Biol 67:102894. https://doi.org/10.1016/j.redox.2023.102894, DOI: 10.1016/j.redox.2023.102894</label>
          <listPosition>54</listPosition>
          <doi>10.1016/j.redox.2023.102894</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283348</mtid>
          <link>/api/reference/55283348</link>
          <label>55. Hofmann U, Knorr S, Vogel B, Weirather J, Frey A, Ertl G, Frantz S (2014) Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction. Circ Heart Fail 7:822–830. https://doi.org/10.1161/CIRCHEARTFAILURE.113.001020, DOI: 10.1161/CIRCHEARTFAILURE.113.001020</label>
          <listPosition>55</listPosition>
          <doi>10.1161/CIRCHEARTFAILURE.113.001020</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283349</mtid>
          <link>/api/reference/55283349</link>
          <label>56. Horenstein MS, Vander Heide RS, L’Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 71:436–444. https://doi.org/10.1006/MGME.2000.3043, DOI: 10.1006/MGME.2000.3043</label>
          <listPosition>56</listPosition>
          <doi>10.1006/MGME.2000.3043</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283350</mtid>
          <link>/api/reference/55283350</link>
          <label>57. Jahn SK, Hennicke T, Kassack MU, Drews L, Reichert AS, Fritz G (2020) Distinct influence of the anthracycline derivative doxorubicin on the differentiation efficacy of mESC-derived endothelial progenitor cells. Biochim Biophys Acta Mol Cell Res. https://doi.org/10.1016/J.BBAMCR.2020.118711, DOI: 10.1016/J.BBAMCR.2020.118711</label>
          <listPosition>57</listPosition>
          <doi>10.1016/J.BBAMCR.2020.118711</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283351</mtid>
          <link>/api/reference/55283351</link>
          <label>58. Jong WMC, Leemans JC, Weber NC, Juffermans NP, Schultz MJ, Hollmann MW, Zuurbier CJ (2014) Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression. Int J Cardiol 177:41–43. https://doi.org/10.1016/J.IJCARD.2014.09.148, DOI: 10.1016/J.IJCARD.2014.09.148</label>
          <listPosition>58</listPosition>
          <doi>10.1016/J.IJCARD.2014.09.148</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283352</mtid>
          <link>/api/reference/55283352</link>
          <label>59. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, De Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC (2018) Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res 24:4960–4967. https://doi.org/10.1158/1078-0432.CCR-17-2386, DOI: 10.1158/1078-0432.CCR-17-2386</label>
          <listPosition>59</listPosition>
          <doi>10.1158/1078-0432.CCR-17-2386</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283353</mtid>
          <link>/api/reference/55283353</link>
          <label>60. Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H (2018) Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 142:1712–1722. https://doi.org/10.1002/IJC.31193, DOI: 10.1002/IJC.31193</label>
          <listPosition>60</listPosition>
          <doi>10.1002/IJC.31193</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283354</mtid>
          <link>/api/reference/55283354</link>
          <label>61. Kelley N, Jeltema D, Duan Y, He Y (2019) The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci 20:3328. https://doi.org/10.3390/IJMS20133328, DOI: 10.3390/IJMS20133328</label>
          <listPosition>61</listPosition>
          <doi>10.3390/IJMS20133328</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283355</mtid>
          <link>/api/reference/55283355</link>
          <label>62. Kenny EM, Fidan E, Yang Q, Anthonymuthu TS, New LA, Meyer EA, Wang H, Kochanek PM, Dixon CE, Kagan VE, Bayir H (2019) Ferroptosis contributes to neuronal death and functional outcome after traumatic brain injury∗. Crit Care Med 47:410–418. https://doi.org/10.1097/CCM.0000000000003555, DOI: 10.1097/CCM.0000000000003555</label>
          <listPosition>62</listPosition>
          <doi>10.1097/CCM.0000000000003555</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283356</mtid>
          <link>/api/reference/55283356</link>
          <label>63. Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T (2009) Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2:15–25. https://doi.org/10.1111/J.1752-8062.2008.00090.X, DOI: 10.1111/J.1752-8062.2008.00090.X</label>
          <listPosition>63</listPosition>
          <doi>10.1111/J.1752-8062.2008.00090.X</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283357</mtid>
          <link>/api/reference/55283357</link>
          <label>64. Khoury MK, Yang H, Liu B (2021) Macrophage biology in cardiovascular diseases. Arterioscler Thromb Vasc Biol 41:E77–E81. https://doi.org/10.1161/ATVBAHA.120.313584, DOI: 10.1161/ATVBAHA.120.313584</label>
          <listPosition>64</listPosition>
          <doi>10.1161/ATVBAHA.120.313584</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283358</mtid>
          <link>/api/reference/55283358</link>
          <label>65. Khunger A, Battel L, Wadhawan A, More A, Kapoor A, Agrawal N (2020) New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity. Curr Oncol Rep. https://doi.org/10.1007/S11912-020-00925-8, DOI: 10.1007/S11912-020-00925-8</label>
          <listPosition>65</listPosition>
          <doi>10.1007/S11912-020-00925-8</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283359</mtid>
          <link>/api/reference/55283359</link>
          <label>66. Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh CM, Jeon JY, Gee HY, Kim JH, Lee BW, Kang ES, Cha BS, Lee MS, Yu JW, Cho JW, Kim JS, Lee YH (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11:1–11. https://doi.org/10.1038/s41467-020-15983-6, DOI: 10.1038/s41467-020-15983-6</label>
          <listPosition>66</listPosition>
          <doi>10.1038/s41467-020-15983-6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283360</mtid>
          <link>/api/reference/55283360</link>
          <label>67. Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD (2016) Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer. https://doi.org/10.1186/S40425-016-0117-1, DOI: 10.1186/S40425-016-0117-1</label>
          <listPosition>67</listPosition>
          <doi>10.1186/S40425-016-0117-1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283361</mtid>
          <link>/api/reference/55283361</link>
          <label>68. Kounatidis D, Vallianou N, Evangelopoulos A, Vlahodimitris I, Grivakou E, Kotsi E, Dimitriou K, Skourtis A, Mourouzis I (2023) SGLT-2 Inhibitors and the inflammasome: what’s next in the 21st century? Nutrients 15:2294. https://doi.org/10.3390/NU15102294, DOI: 10.3390/NU15102294</label>
          <listPosition>68</listPosition>
          <doi>10.3390/NU15102294</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283362</mtid>
          <link>/api/reference/55283362</link>
          <label>69. Kuang H, Liao L, Chen H, Kang Q, Shu X, Wang Y (2017) Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma. Med Sci Monit 23:3737–3745. https://doi.org/10.12659/MSM.902530, DOI: 10.12659/MSM.902530</label>
          <listPosition>69</listPosition>
          <doi>10.12659/MSM.902530</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283363</mtid>
          <link>/api/reference/55283363</link>
          <label>70. Lau KTK, Ng L, Wong JWH, Loong HHF, Chan WWL, Lee CH, Wong CKH (2021) Repurposing sodium–glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment—a review. Rev Endocr Metab Disord 22:1121–1136. https://doi.org/10.1007/S11154-021-09675-9, DOI: 10.1007/S11154-021-09675-9</label>
          <listPosition>70</listPosition>
          <doi>10.1007/S11154-021-09675-9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283364</mtid>
          <link>/api/reference/55283364</link>
          <label>71. Lauritsen KM, Søndergaard E, Svart M, Møller N, Gormsen LC (2018) Ketone body infusion increases circulating erythropoietin and bone marrow glucose uptake. Diabetes Care 41:e152–e154. https://doi.org/10.2337/DC18-1421, DOI: 10.2337/DC18-1421</label>
          <listPosition>71</listPosition>
          <doi>10.2337/DC18-1421</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283365</mtid>
          <link>/api/reference/55283365</link>
          <label>72. Lauritsen KM, Voigt JH, Pedersen SB, Hansen TK, Møller N, Jessen N, Gormsen LC, Søndergaard E (2022) Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes. Endocr Connect. https://doi.org/10.1530/EC-21-0558, DOI: 10.1530/EC-21-0558</label>
          <listPosition>72</listPosition>
          <doi>10.1530/EC-21-0558</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283366</mtid>
          <link>/api/reference/55283366</link>
          <label>73. Lavine KJ, Pinto AR, Epelman S, Kopecky BJ, Clemente-Casares X, Godwin J, Rosenthal N, Kovacic JC (2018) The macrophage in cardiac homeostasis and disease: JACC macrophage in CVD series (Part 4). J Am Coll Cardiol 72:2213–2230. https://doi.org/10.1016/J.JACC.2018.08.2149, DOI: 10.1016/J.JACC.2018.08.2149</label>
          <listPosition>73</listPosition>
          <doi>10.1016/J.JACC.2018.08.2149</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283367</mtid>
          <link>/api/reference/55283367</link>
          <label>74. Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ (2021) Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 signalling pathways. J Immunol Res. https://doi.org/10.1155/2021/9944880, DOI: 10.1155/2021/9944880</label>
          <listPosition>74</listPosition>
          <doi>10.1155/2021/9944880</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283368</mtid>
          <link>/api/reference/55283368</link>
          <label>75. Lee TI, Chen YC, Lin YK, Chung CC, Lu YY, Kao YH, Chen YJ (2019) Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats. Int J Mol Sci 20:1680. https://doi.org/10.3390/IJMS20071680, DOI: 10.3390/IJMS20071680</label>
          <listPosition>75</listPosition>
          <doi>10.3390/IJMS20071680</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283369</mtid>
          <link>/api/reference/55283369</link>
          <label>76. Lee TM, Chang NC, Lin SZ (2017) Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104:298–310. https://doi.org/10.1016/J.FREERADBIOMED.2017.01.035, DOI: 10.1016/J.FREERADBIOMED.2017.01.035</label>
          <listPosition>76</listPosition>
          <doi>10.1016/J.FREERADBIOMED.2017.01.035</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283370</mtid>
          <link>/api/reference/55283370</link>
          <label>77. Li J, Yu Y, Sun Y, Yu B, Tan X, Wang B, Lu Y, Wang N (2023) SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a mendelian randomization study. Cardiovasc Diabetol 22:278. https://doi.org/10.1186/s12933-023-02019-8, DOI: 10.1186/s12933-023-02019-8</label>
          <listPosition>77</listPosition>
          <doi>10.1186/s12933-023-02019-8</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283371</mtid>
          <link>/api/reference/55283371</link>
          <label>78. Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211–218. https://doi.org/10.1016/j.tibs.2015.12.001, DOI: 10.1016/j.tibs.2015.12.001</label>
          <listPosition>78</listPosition>
          <doi>10.1016/j.tibs.2015.12.001</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283372</mtid>
          <link>/api/reference/55283372</link>
          <label>79. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma MJ, Nakagawa T, Kusaka H, Kim-Mitsuyama S (2014) Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. https://doi.org/10.1186/S12933-014-0148-1, DOI: 10.1186/S12933-014-0148-1</label>
          <listPosition>79</listPosition>
          <doi>10.1186/S12933-014-0148-1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283373</mtid>
          <link>/api/reference/55283373</link>
          <label>80. Lin M, Xiong W, Wang S, Li Y, Hou C, Li C, Li G (2022) The Research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment. Front Cardiovasc Med 8:821663. https://doi.org/10.3389/FCVM.2021.821663, DOI: 10.3389/FCVM.2021.821663</label>
          <listPosition>80</listPosition>
          <doi>10.3389/FCVM.2021.821663</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283374</mtid>
          <link>/api/reference/55283374</link>
          <label>81. Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, Prokai A, Zuchtriegel G, Krombach F, Welz PS, Weinlich R, Vanden BT, Vandenabeele P, Pasparakis M, Bleich M, Weinberg JM, Reichel CA, Bräsen JH, Kunzendorf U, Anders HJ, Stockwell BR, Green DR, Krautwald S (2014) Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci U S A 111:16836–16841. https://doi.org/10.1073/PNAS.1415518111/SUPPL_FILE/PNAS.1415518111.SM04.AVI, DOI: 10.1073/PNAS.1415518111/SUPPL_FILE/PNAS.1415518111.SM04.AVI</label>
          <listPosition>81</listPosition>
          <doi>10.1073/PNAS.1415518111/SUPPL_FILE/PNAS.1415518111.SM04.AVI</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283375</mtid>
          <link>/api/reference/55283375</link>
          <label>82. Lőrincz T, Jemnitz K, Kardon T, Mandl J, Szarka A (2015) Ferroptosis is involved in acetaminophen induced cell death. Pathol Oncol Res 21:1115–1121. https://doi.org/10.1007/S12253-015-9946-3, DOI: 10.1007/S12253-015-9946-3</label>
          <listPosition>82</listPosition>
          <doi>10.1007/S12253-015-9946-3</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283376</mtid>
          <link>/api/reference/55283376</link>
          <label>83. Ma S, He LL, Zhang GR, Zuo QJ, Wang ZL, Zhai JL, Zhang TT, Wang Y, Ma HJ, Guo YF (2022) Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction. Naunyn Schmiedebergs Arch Pharmacol 395:945–962. https://doi.org/10.1007/S00210-022-02243-1/FIGURES/9, DOI: 10.1007/S00210-022-02243-1/FIGURES/9</label>
          <listPosition>83</listPosition>
          <doi>10.1007/S00210-022-02243-1/FIGURES/9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283377</mtid>
          <link>/api/reference/55283377</link>
          <label>84. Madonna R, Cadeddu C, Deidda M, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Zito C, Mercuro G (2015) Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a position paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev 20:621–631. https://doi.org/10.1007/S10741-015-9497-4, DOI: 10.1007/S10741-015-9497-4</label>
          <listPosition>84</listPosition>
          <doi>10.1007/S10741-015-9497-4</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283378</mtid>
          <link>/api/reference/55283378</link>
          <label>85. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686. https://doi.org/10.1016/j.it.2004.09.015, DOI: 10.1016/j.it.2004.09.015</label>
          <listPosition>85</listPosition>
          <doi>10.1016/j.it.2004.09.015</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283379</mtid>
          <link>/api/reference/55283379</link>
          <label>86. Mascolo A, Scavone C, Ferrajolo C et al (2021) Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance. Drug Saf 44:957–971, DOI: 10.1007/s40264-021-01086-8</label>
          <listPosition>86</listPosition>
          <doi>10.1007/s40264-021-01086-8</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283380</mtid>
          <link>/api/reference/55283380</link>
          <label>87. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777–4786. https://doi.org/10.1038/SJ.ONC.1209603, DOI: 10.1038/SJ.ONC.1209603</label>
          <listPosition>87</listPosition>
          <doi>10.1038/SJ.ONC.1209603</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283381</mtid>
          <link>/api/reference/55283381</link>
          <label>88. Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, Teoh H, Leiter LA, Zinman B, Jüni P, Zuo F, Mistry N, Thorpe KE, Goldenberg RM, Yan AT, Connelly KA, Verma S (2020) Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 141:704–707. https://doi.org/10.1161/CIRCULATIONAHA.119.044235, DOI: 10.1161/CIRCULATIONAHA.119.044235</label>
          <listPosition>88</listPosition>
          <doi>10.1161/CIRCULATIONAHA.119.044235</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283382</mtid>
          <link>/api/reference/55283382</link>
          <label>89. McDonagh TA, Metra M, Adamo M, Baumbach A, Böhm M, Burri H, Čelutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gardner RS, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, de Boer RA, Schulze PC, Abdelhamid M, Aboyans V, Adamopoulos S, Anker SD, Arbelo E, Asteggiano R, Bauersachs J, Bayes-Genis A, Borger MA, Budts W, Cikes M, Damman K, Delgado V, Dendale P, Dilaveris P, Drexel H, Ezekowitz J, Falk V, Fauchier L, Filippatos G, Fraser A, Frey N, Gale CP, Gustafsson F, Harris J, Iung B, Janssens S, Jessup M, Konradi A, Kotecha D, Lambrinou E, Lancellotti P, Landmesser U, Leclercq C, Lewis BS, Leyva F, Linhart A, Løchen ML, Lund LH, Mancini D, Masip J, Milicic D, Mueller C, Nef H, Nielsen JC, Neubeck L, Noutsias M, Petersen SE, Petronio AS, Ponikowski P, Prescott E, Rakisheva A, Richter D, Schlyakhto E, Seferovic P, Senni M, Sitges M, Sousa-Uva M, Tocchetti CG, Touyz R, Tschoepe C, Waltenberger J, Krim M, Hayrapetyan H, Moertl D, Mustafayev I, Kurlianskaya A, Depauw M, Kušljugić Z, Gatzov P, Agathangelou P, Melenovský V, Løgstrup BB, Mostafa AM, Uuetoa T, Lassus J, Logeart D, Kipiani Z, Chrysohoou C, Sepp R, Ingimarsdóttir IJ, O’Neill J, Gotsman I, Iacoviello M, Bajraktari G, Lunegova O, Kamzola G, Massih TA, Benlamin H, Žaliaduonyte D, Noppe S, Moore A, Vataman E, Boskovic A, Bennis A, Manintveld OC, Kostovska ES, Gulati G, Straburzyńska-Migaj E, Silva-Cardoso J, Rimbaş RC, Lopatin Y, Foscoli M, Stojkovic S, Goncalvesova E, Fras Z, Segovia J, Lindmark K, Maeder MT, Bsata W, Abid L, Altay H, Voronkov L, Davies C, Abdullaev T, Baigent CN, Antoniou S, Collet JP, Halvorsen S, Koskinas KC (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726. https://doi.org/10.1093/EURHEARTJ/EHAB368, DOI: 10.1093/EURHEARTJ/EHAB368</label>
          <listPosition>89</listPosition>
          <doi>10.1093/EURHEARTJ/EHAB368</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283383</mtid>
          <link>/api/reference/55283383</link>
          <label>90. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, de Boer RA, Schulze PC, Arbelo E, Bartunek J, Bauersachs J, Borger MA, Buccheri S, Cerbai E, Donal E, Edelmann F, Färber G, Heidecker B, Ibanez B, James S, Køber L, Koskinas KC, Masip J, McEvoy JW, Mentz R, Mihaylova B, Møller JE, Mullens W, Neubeck L, Nielsen JC, Pasquet AA, Ponikowski P, Prescott E, Rakisheva A, Rocca B, Rossello X, Sade LE, Schaubroeck H, Tessitore E, Tokmakova M, van der Meer P, Van Gelder IC, Van Heetvelde M, Vrints C, Wilhelm M, Witkowski A, Zeppenfeld K, Shuka N, Chettibi M, Hayrapetyan H, Pavo N, Islamli A, Pouleur A-C, Kusljugic Z, Tokmakova M, Milicic D, Christodoulides T, Malek F, Køber L, Koriem MAG, Põder P, Lassus J, Roubille F, Agladze V, Frantz S, Stavrati A, Kosztin A, Ingimarsdóttir IJ, Campbell P, Hasin T, Oliva F, Aidargaliyeva N, Bajraktari G, Mirrakhimov E, Kamzola G, El Neihoum AM, Zaliaduonyte D, Moore A, Vataman E, Boskovic A, Alami M, Manintveld O, Kostovska ES, Broch K, Nessler J, Franco F, Popescu BA, Foscoli M, Milosavljevic AS, Goncalvesova E, Fras Z, Gonzalez-Costello J, Lindmark K, Paul M, Oudeh A, Zakhama L, Celik A, Voronkov L, Clark A, Abdullaev T, Prescott E, James S, Arbelo E, Baigent C, Borger MA, Buccheri S, Ibanez B, Køber L, Koskinas KC, McEvoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Pasquet AA, Rakisheva A, Rocca B, Rossello X, Vaartjes I, Vrints C, Witkowski A, Zeppenfeld K (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. https://doi.org/10.1093/EURHEARTJ/EHAD195, DOI: 10.1093/EURHEARTJ/EHAD195</label>
          <listPosition>90</listPosition>
          <doi>10.1093/EURHEARTJ/EHAD195</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283384</mtid>
          <link>/api/reference/55283384</link>
          <label>91. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMOA1911303, DOI: 10.1056/NEJMOA1911303</label>
          <listPosition>91</listPosition>
          <doi>10.1056/NEJMOA1911303</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283385</mtid>
          <link>/api/reference/55283385</link>
          <label>92. Melloni C, Shrader P, Carver J, Piccini JP, Thomas L, Fonarow GC, Ansell J, Gersh B, Go AS, Hylek E, Herling IM, Mahaffey KW, Yu AF, Peterson ED, Kowey PR (2017) Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes 3:192–197. https://doi.org/10.1093/EHJQCCO/QCX004, DOI: 10.1093/EHJQCCO/QCX004</label>
          <listPosition>92</listPosition>
          <doi>10.1093/EHJQCCO/QCX004</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283386</mtid>
          <link>/api/reference/55283386</link>
          <label>93. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, Abbate A (2011) The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 108:19725–19730. https://doi.org/10.1073/PNAS.1108586108/SUPPL_FILE/PNAS.201108586SI.PDF, DOI: 10.1073/PNAS.1108586108/SUPPL_FILE/PNAS.201108586SI.PDF</label>
          <listPosition>93</listPosition>
          <doi>10.1073/PNAS.1108586108/SUPPL_FILE/PNAS.201108586SI.PDF</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283387</mtid>
          <link>/api/reference/55283387</link>
          <label>94. Min J, Wu L, Liu Y, Song G, Deng Q, Jin W, Yu W, Miyesaier A, Pei Z, Ren J (2023) Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci 312:121207. https://doi.org/10.1016/J.LFS.2022.121207, DOI: 10.1016/J.LFS.2022.121207</label>
          <listPosition>94</listPosition>
          <doi>10.1016/J.LFS.2022.121207</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283388</mtid>
          <link>/api/reference/55283388</link>
          <label>95. Minotti G, Menna P, Camilli M, Salvatorelli E, Levi R (2022) Beyond hypertension: diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Adv Pharmacol 94:365–409. https://doi.org/10.1016/BS.APHA.2022.02.002, DOI: 10.1016/BS.APHA.2022.02.002</label>
          <listPosition>95</listPosition>
          <doi>10.1016/BS.APHA.2022.02.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283389</mtid>
          <link>/api/reference/55283389</link>
          <label>96. Minotti G, Reggiardo G, Camilli M, Salvatorelli E, Menna P (2022) From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach. Cardio Oncology 4:139–140. https://doi.org/10.1016/J.JACCAO.2021.12.002, DOI: 10.1016/J.JACCAO.2021.12.002</label>
          <listPosition>96</listPosition>
          <doi>10.1016/J.JACCAO.2021.12.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283390</mtid>
          <link>/api/reference/55283390</link>
          <label>97. Monica Reddy RP, Inzucchi SE (2016) SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53:364–372. https://doi.org/10.1007/S12020-016-0943-4, DOI: 10.1007/S12020-016-0943-4</label>
          <listPosition>97</listPosition>
          <doi>10.1007/S12020-016-0943-4</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283391</mtid>
          <link>/api/reference/55283391</link>
          <label>98. Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B (1998) Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 9:1109–1115. https://doi.org/10.1023/A:1008498705032, DOI: 10.1023/A:1008498705032</label>
          <listPosition>98</listPosition>
          <doi>10.1023/A:1008498705032</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283392</mtid>
          <link>/api/reference/55283392</link>
          <label>99. Nakachi S, Okamoto S, Tamaki K, Nomura I, Tomihama M, Nishi Y, Fukushima T, Tanaka Y, Morishima S, Imamura M, Maeda S, Tsutsui M, Matsushita M, Masuzaki H (2022) Impact of anti-diabetic sodium–glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans. Biomed Pharmacother. https://doi.org/10.1016/J.BIOPHA.2022.112864, DOI: 10.1016/J.BIOPHA.2022.112864</label>
          <listPosition>99</listPosition>
          <doi>10.1016/J.BIOPHA.2022.112864</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283393</mtid>
          <link>/api/reference/55283393</link>
          <label>100. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMOA1611925/SUPPL_FILE/NEJMOA1611925_DISCLOSURES.PDF, DOI: 10.1056/NEJMOA1611925/SUPPL_FILE/NEJMOA1611925_DISCLOSURES.PDF</label>
          <listPosition>100</listPosition>
          <doi>10.1056/NEJMOA1611925/SUPPL_FILE/NEJMOA1611925_DISCLOSURES.PDF</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283394</mtid>
          <link>/api/reference/55283394</link>
          <label>101. Nikolaou PE, Efentakis P, Abu Qourah F, Femminò S, Makridakis M, Kanaki Z, Varela A, Tsoumani M, Davos CH, Dimitriou CA, Tasouli A, Dimitriadis G, Kostomitsopoulos N, Zuurbier CJ, Vlahou A, Klinakis A, Brizzi MF, Iliodromitis EK, Andreadou I (2021) Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress. Antioxid Redox Signal 34:551–571. https://doi.org/10.1089/ARS.2019.7923, DOI: 10.1089/ARS.2019.7923</label>
          <listPosition>101</listPosition>
          <doi>10.1089/ARS.2019.7923</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283395</mtid>
          <link>/api/reference/55283395</link>
          <label>102. Oh CM, Cho S, Jang JY, Kim H, Chun S, Choi M, Park S, Ko YG (2019) Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J 49:1183–1195. https://doi.org/10.4070/KCJ.2019.0180, DOI: 10.4070/KCJ.2019.0180</label>
          <listPosition>102</listPosition>
          <doi>10.4070/KCJ.2019.0180</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283396</mtid>
          <link>/api/reference/55283396</link>
          <label>103. Packer M (2022) How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure. Eur J Heart Fail 24:2287–2296. https://doi.org/10.1002/EJHF.2731, DOI: 10.1002/EJHF.2731</label>
          <listPosition>103</listPosition>
          <doi>10.1002/EJHF.2731</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283397</mtid>
          <link>/api/reference/55283397</link>
          <label>104. Packer M (2023) Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors. Eur Heart J. https://doi.org/10.1093/EURHEARTJ/EHAD235, DOI: 10.1093/EURHEARTJ/EHAD235</label>
          <listPosition>104</listPosition>
          <doi>10.1093/EURHEARTJ/EHAD235</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283398</mtid>
          <link>/api/reference/55283398</link>
          <label>105. Park LK, Lim K-H, Volkman J, Abdiannia M, Johnston H, Nigogosyan Z, Siegel MJ, McGill JB, McKee AM, Salam M, Zhang RM, Ma D, Popuri K, Chow VTY, Beg MF, Hawkins WG, Peterson LR (2023) Safety, tolerability, and effectiveness of the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study. Cancer Metab 11:1–12. https://doi.org/10.1186/S40170-023-00306-2, DOI: 10.1186/S40170-023-00306-2</label>
          <listPosition>105</listPosition>
          <doi>10.1186/S40170-023-00306-2</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283399</mtid>
          <link>/api/reference/55283399</link>
          <label>106. Park TJ, Park JH, Lee GS, Lee JY, Shin JH, Kim MW, Kim YS, Kim JY, Oh KJ, Han BS, Kim WK, Ahn Y, Moon JH, Song J, Bae KH, Kim DH, Lee EW, Lee SC (2019) Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes. Cell Death Dis 10:835. https://doi.org/10.1038/S41419-019-2061-8, DOI: 10.1038/S41419-019-2061-8</label>
          <listPosition>106</listPosition>
          <doi>10.1038/S41419-019-2061-8</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283400</mtid>
          <link>/api/reference/55283400</link>
          <label>107. Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, Füner L, Härdtner C, Stachon P, Wolf D, Hilgendorf I, Mullick A, Bode C, Zirlik A, Goldberg IJ, Willecke F (2019) Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. Sci Rep 9:1–12. https://doi.org/10.1038/s41598-019-54224-9, DOI: 10.1038/s41598-019-54224-9</label>
          <listPosition>107</listPosition>
          <doi>10.1038/s41598-019-54224-9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283401</mtid>
          <link>/api/reference/55283401</link>
          <label>108. Perelman MG, Brzezinski RY, Waissengrin B, Leshem Y, Bainhoren O, Rubinstein TA, Perelman M, Rozenbaum Z, Havakuk O, Topilsky Y, Banai S, Wolf I, Laufer-Perl M (2024) Sodium–glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardiooncology. https://doi.org/10.1186/S40959-023-00199-6, DOI: 10.1186/S40959-023-00199-6</label>
          <listPosition>108</listPosition>
          <doi>10.1186/S40959-023-00199-6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283402</mtid>
          <link>/api/reference/55283402</link>
          <label>109. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMRA1703481, DOI: 10.1056/NEJMRA1703481</label>
          <listPosition>109</listPosition>
          <doi>10.1056/NEJMRA1703481</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283403</mtid>
          <link>/api/reference/55283403</link>
          <label>110. Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang Z, Wang X (2019) The diverse function of PD-1/PD-L pathway beyond cancer. Front Immunol. https://doi.org/10.3389/FIMMU.2019.02298, DOI: 10.3389/FIMMU.2019.02298</label>
          <listPosition>110</listPosition>
          <doi>10.3389/FIMMU.2019.02298</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283404</mtid>
          <link>/api/reference/55283404</link>
          <label>111. Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M, Canale ML, Botti G, Maurea N (2021) The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. https://doi.org/10.1186/S12933-021-01346-Y, DOI: 10.1186/S12933-021-01346-Y</label>
          <listPosition>111</listPosition>
          <doi>10.1186/S12933-021-01346-Y</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283405</mtid>
          <link>/api/reference/55283405</link>
          <label>112. Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, Kalathoor S, Ferdousi M, Krishan S, Habib A, Shaaban A, Kola-Kehinde O, Kittai AS, Rogers KA, Grever M, Ruz P, Bhat S, Dickerson T, Byrd JC, Woyach J, Addison D (2023) Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 5:570–590. https://doi.org/10.1016/J.JACCAO.2023.09.002, DOI: 10.1016/J.JACCAO.2023.09.002</label>
          <listPosition>112</listPosition>
          <doi>10.1016/J.JACCAO.2023.09.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283406</mtid>
          <link>/api/reference/55283406</link>
          <label>113. Refaie MMM, Shehata S, El-Hussieny M, Fawzy MA, Ahmed NZM, Marey H, Hishmat AM, Alkully T, El RESMA (2023) Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNFα/TLR/NF-κB signaling pathway in rats. Toxicol Res 40:139–151. https://doi.org/10.1007/S43188-023-00204-1, DOI: 10.1007/S43188-023-00204-1</label>
          <listPosition>113</listPosition>
          <doi>10.1007/S43188-023-00204-1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283407</mtid>
          <link>/api/reference/55283407</link>
          <label>114. Reis-Mendes A, Padrão AI, Duarte JA, Gonçalves-Monteiro S, Duarte-Araújo M, Remião F, Carvalho F, Sousa E, Bastos ML, Costa VM (2021) Role of inflammation and redox status on doxorubicin-induced cardiotoxicity in infant and adult CD-1 male mice. Biomolecules. https://doi.org/10.3390/BIOM11111725, DOI: 10.3390/BIOM11111725</label>
          <listPosition>114</listPosition>
          <doi>10.3390/BIOM11111725</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283408</mtid>
          <link>/api/reference/55283408</link>
          <label>115. Ren C, Sun K, Zhang Y, Hu Y, Hu B, Zhao J, He Z, Ding R, Wang W, Liang C (2021) Sodium–glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy. Front Pharmacol. https://doi.org/10.3389/FPHAR.2021.664181, DOI: 10.3389/FPHAR.2021.664181</label>
          <listPosition>115</listPosition>
          <doi>10.3389/FPHAR.2021.664181</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283409</mtid>
          <link>/api/reference/55283409</link>
          <label>116. Renu K, Abilash VG, Tirupathi TP, Arunachalam S (2017) Molecular mechanism of doxorubicin-induced cardiomyopathy—an update. Eur J Pharmacol 818:241–253. https://doi.org/10.1016/J.EJPHAR.2017.10.043, DOI: 10.1016/J.EJPHAR.2017.10.043</label>
          <listPosition>116</listPosition>
          <doi>10.1016/J.EJPHAR.2017.10.043</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283410</mtid>
          <link>/api/reference/55283410</link>
          <label>117. Riehle C, Abel ED (2012) PGC-1 proteins and heart failure. Trends Cardiovasc Med 22:98–105. https://doi.org/10.1016/J.TCM.2012.07.003, DOI: 10.1016/J.TCM.2012.07.003</label>
          <listPosition>117</listPosition>
          <doi>10.1016/J.TCM.2012.07.003</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283411</mtid>
          <link>/api/reference/55283411</link>
          <label>118. Rogava M, Aprati TJ, Chi WY, Melms JC, Hug C, Davis SH, Earlie EM, Chung C, Deshmukh SK, Wu S, Sledge G, Tang S, Ho P, Amin AD, Caprio L, Gurjao C, Tagore S, Ngo B, Lee MJ, Zanetti G, Wang Y, Chen S, Ge W, Melo LMN, Allies G, Rösler J, Gibney GT, Schmitz OJ, Sykes M, Creusot RJ, Tüting T, Schadendorf D, Röcken M, Eigentler TK, Molotkov A, Mintz A, Bakhoum SF, Beyaz S, Cantley LC, Sorger PK, Meckelmann SW, Tasdogan A, Liu D, Laughney AM, Izar B (2024) Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation. Nat Cancer. https://doi.org/10.1038/S43018-023-00704-X, DOI: 10.1038/S43018-023-00704-X</label>
          <listPosition>118</listPosition>
          <doi>10.1038/S43018-023-00704-X</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283412</mtid>
          <link>/api/reference/55283412</link>
          <label>119. Rokszin G, Kiss Z, Sütő G, Kempler P, Jermendy G, Fábián I, Szekanecz Z, Poór G, Wittmann I, Molnár GA (2021) Sodium–glucose co-transporter 2 inhibitors may change the development of urinary tract and hematological malignancies as compared with dipeptidyl peptidase-4 inhibitors: data of the post-hoc analysis of a nationwide study. Front Oncol. https://doi.org/10.3389/FONC.2021.725465, DOI: 10.3389/FONC.2021.725465</label>
          <listPosition>119</listPosition>
          <doi>10.3389/FONC.2021.725465</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283413</mtid>
          <link>/api/reference/55283413</link>
          <label>120. Ryaboshapkina M, Ye R, Ye Y, Birnbaum Y (2023) Effects of dapagliflozin on myocardial gene expression in btbr mice with type 2 diabetes. Cardiovasc Drugs Ther. https://doi.org/10.1007/s10557-023-07517-1, DOI: 10.1007/s10557-023-07517-1</label>
          <listPosition>120</listPosition>
          <doi>10.1007/s10557-023-07517-1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283414</mtid>
          <link>/api/reference/55283414</link>
          <label>121. Sabatino J, De Rosa S, Tammè L, Iaconetti C, Sorrentino S, Polimeni A, Mignogna C, Amorosi A, Spaccarotella C, Yasuda M, Indolfi C (2020) Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol 19:66. https://doi.org/10.1186/S12933-020-01040-5, DOI: 10.1186/S12933-020-01040-5</label>
          <listPosition>121</listPosition>
          <doi>10.1186/S12933-020-01040-5</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283415</mtid>
          <link>/api/reference/55283415</link>
          <label>122. Salloum FN, Tocchetti CG, Ameri P, Ardehali H, Asnani A, de Boer RA, Burridge P, Cabrera JÁ, de Castro J, Córdoba R, Costa A, Dent S, Engelbertsen D, Fernández-Velasco M, Fradley M, Fuster JJ, Galán-Arriola C, García-Lunar I, Ghigo A, González-Neira A, Hirsch E, Ibáñez B, Kitsis RN, Konety S, Lyon AR, Martin P, Mauro AG, Mazo Vega MM, Meijers WC, Neilan TG, Rassaf T, Ricke-Hoch M, Sepulveda P, Thavendiranathan P, van der Meer P, Fuster V, Ky B, López-Fernández T (2023) Priorities in cardio-oncology basic and translational science: GCOS 2023 symposium proceedings: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 5:715–731. https://doi.org/10.1016/J.JACCAO.2023.08.003, DOI: 10.1016/J.JACCAO.2023.08.003</label>
          <listPosition>122</listPosition>
          <doi>10.1016/J.JACCAO.2023.08.003</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283416</mtid>
          <link>/api/reference/55283416</link>
          <label>123. Sandanger GE, Ranheim T, Bliksøen M, Kaasbøll OJ, Alfsnes K, Nymo SH, Rashidi A, Ohm IK, Attramadal H, Aukrust P, Vinge LE, Yndestad A (2016) NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective. Biochem Biophys Res Commun 469:1012–1020. https://doi.org/10.1016/J.BBRC.2015.12.051, DOI: 10.1016/J.BBRC.2015.12.051</label>
          <listPosition>123</listPosition>
          <doi>10.1016/J.BBRC.2015.12.051</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283417</mtid>
          <link>/api/reference/55283417</link>
          <label>124. Sano M, Goto S (2019) Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139:1985–1987. https://doi.org/10.1161/CIRCULATIONAHA.118.038881, DOI: 10.1161/CIRCULATIONAHA.118.038881</label>
          <listPosition>124</listPosition>
          <doi>10.1161/CIRCULATIONAHA.118.038881</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283418</mtid>
          <link>/api/reference/55283418</link>
          <label>125. Sawyer DB (2013) Anthracyclines and heart failure. N Engl J Med 368:1154–1156. https://doi.org/10.1056/NEJMCIBR1214975/SUPPL_FILE/NEJMCIBR1214975_DISCLOSURES.PDF, DOI: 10.1056/NEJMCIBR1214975/SUPPL_FILE/NEJMCIBR1214975_DISCLOSURES.PDF</label>
          <listPosition>125</listPosition>
          <doi>10.1056/NEJMCIBR1214975/SUPPL_FILE/NEJMCIBR1214975_DISCLOSURES.PDF</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283419</mtid>
          <link>/api/reference/55283419</link>
          <label>126. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84:257–265. https://doi.org/10.1161/01.RES.84.3.257, DOI: 10.1161/01.RES.84.3.257</label>
          <listPosition>126</listPosition>
          <doi>10.1161/01.RES.84.3.257</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283420</mtid>
          <link>/api/reference/55283420</link>
          <label>127. Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, Moatamed NA, Huang J, Koepsell H, Barrio JR, Wright EM (2015) Functional expression of sodium–glucose transporters in cancer. Proc Natl Acad Sci U S A 112:E4111–E4119. https://doi.org/10.1073/PNAS.1511698112, DOI: 10.1073/PNAS.1511698112</label>
          <listPosition>127</listPosition>
          <doi>10.1073/PNAS.1511698112</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283421</mtid>
          <link>/api/reference/55283421</link>
          <label>128. Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Puocci A, De Angelis A, Sportiello L, Marfella R, Barbieri M (2022) Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med. https://doi.org/10.3389/FCVM.2022.1008922, DOI: 10.3389/FCVM.2022.1008922</label>
          <listPosition>128</listPosition>
          <doi>10.3389/FCVM.2022.1008922</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283422</mtid>
          <link>/api/reference/55283422</link>
          <label>129. Shiga T, Hiraide M (2020) Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines. Curr Treat Options Oncol. https://doi.org/10.1007/S11864-020-0719-1, DOI: 10.1007/S11864-020-0719-1</label>
          <listPosition>129</listPosition>
          <doi>10.1007/S11864-020-0719-1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283423</mtid>
          <link>/api/reference/55283423</link>
          <label>130. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang C-E, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089–1098. https://doi.org/10.1056/NEJMOA2206286/SUPPL_FILE/NEJMOA2206286_DATA-SHARING.PDF, DOI: 10.1056/NEJMOA2206286/SUPPL_FILE/NEJMOA2206286_DATA-SHARING.PDF</label>
          <listPosition>130</listPosition>
          <doi>10.1056/NEJMOA2206286/SUPPL_FILE/NEJMOA2206286_DATA-SHARING.PDF</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283424</mtid>
          <link>/api/reference/55283424</link>
          <label>131. Sun L, Wang H, Yu S, Zhang L, Jiang J, Zhou Q (2022) Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells. Int J Mol Med 49:1–8. https://doi.org/10.3892/IJMM.2021.5072/HTML, DOI: 10.3892/IJMM.2021.5072/HTML</label>
          <listPosition>131</listPosition>
          <doi>10.3892/IJMM.2021.5072/HTML</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283425</mtid>
          <link>/api/reference/55283425</link>
          <label>132. Swe MT, Thongnak L, Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Lungkaphin A (2019) Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Clin Sci 133:2415–2430. https://doi.org/10.1042/CS20190863, DOI: 10.1042/CS20190863</label>
          <listPosition>132</listPosition>
          <doi>10.1042/CS20190863</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283426</mtid>
          <link>/api/reference/55283426</link>
          <label>133. Szekeres Z, Toth K, Szabados E (2021) The effects of SGLT2 inhibitors on lipid metabolism. Metabolites 11:1–9. https://doi.org/10.3390/METABO11020087, DOI: 10.3390/METABO11020087</label>
          <listPosition>133</listPosition>
          <doi>10.3390/METABO11020087</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283427</mtid>
          <link>/api/reference/55283427</link>
          <label>134. Tan TC, Neilan TG, Francis S, Plana JC, Scherrer-Crosbie M (2015) Anthracycline-induced cardiomyopathy in adults. Compr Physiol 5:1517–1540. https://doi.org/10.1002/CPHY.C140059, DOI: 10.1002/CPHY.C140059</label>
          <listPosition>134</listPosition>
          <doi>10.1002/CPHY.C140059</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283428</mtid>
          <link>/api/reference/55283428</link>
          <label>135. Tewey KM, Chenb GL, Nelsonf EM, Lius LF (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase 11. J Biol Chem 259:9182–9187. https://doi.org/10.1016/S0021-9258(17)47282-6, DOI: 10.1016/S0021-9258(17)47282-6</label>
          <listPosition>135</listPosition>
          <doi>10.1016/S0021-9258(17)47282-6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283429</mtid>
          <link>/api/reference/55283429</link>
          <label>136. Tisi MC, Bozzoli V, Giachelia M, Massini G, Ricerca BM, Maiolo E, D’Alo F, Larocca LM, Piciocchi A, Tjalsma H, Swinkels DW, Voso MT, Leone G, Hohaus S (2014) Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma 55:270–275. https://doi.org/10.3109/10428194.2013.802314, DOI: 10.3109/10428194.2013.802314</label>
          <listPosition>136</listPosition>
          <doi>10.3109/10428194.2013.802314</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283430</mtid>
          <link>/api/reference/55283430</link>
          <label>137. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389–405. https://doi.org/10.1016/J.YJMCC.2006.06.009, DOI: 10.1016/J.YJMCC.2006.06.009</label>
          <listPosition>137</listPosition>
          <doi>10.1016/J.YJMCC.2006.06.009</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283431</mtid>
          <link>/api/reference/55283431</link>
          <label>138. Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T (2019) Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163–175. https://doi.org/10.1016/j.ijcard.2019.01.038, DOI: 10.1016/j.ijcard.2019.01.038</label>
          <listPosition>138</listPosition>
          <doi>10.1016/j.ijcard.2019.01.038</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283432</mtid>
          <link>/api/reference/55283432</link>
          <label>139. Tsuchiya T, Kominato Y, Ueda M (2002) Human hypoxic signal transduction through a signature motif in hepatocyte nuclear factor 4. J Biochem 132:37–44. https://doi.org/10.1093/OXFORDJOURNALS.JBCHEM.A003196, DOI: 10.1093/OXFORDJOURNALS.JBCHEM.A003196</label>
          <listPosition>139</listPosition>
          <doi>10.1093/OXFORDJOURNALS.JBCHEM.A003196</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283433</mtid>
          <link>/api/reference/55283433</link>
          <label>140. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson IM, Edlund K, Lundberg E, Navani S, Szigyarto CAK, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, Von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, Von Heijne G, Nielsen J, Pontén F (2015) Tissue-based map of the human proteome. Science 1979:347. https://doi.org/10.1126/SCIENCE.1260419/SUPPL_FILE/1260419_UHLEN.SM.PDF, DOI: 10.1126/SCIENCE.1260419/SUPPL_FILE/1260419_UHLEN.SM.PDF</label>
          <listPosition>140</listPosition>
          <doi>10.1126/SCIENCE.1260419/SUPPL_FILE/1260419_UHLEN.SM.PDF</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283434</mtid>
          <link>/api/reference/55283434</link>
          <label>141. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 61:722–726. https://doi.org/10.1007/S00125-017-4509-7, DOI: 10.1007/S00125-017-4509-7</label>
          <listPosition>141</listPosition>
          <doi>10.1007/S00125-017-4509-7</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283435</mtid>
          <link>/api/reference/55283435</link>
          <label>142. Uthman L, Kuschma M, Römer G, Boomsma M, Kessler J, Hermanides J, Hollmann MW, Preckel B, Zuurbier CJ, Weber NC (2021) Novel anti-inflammatory effects of canagliflozin involving hexokinase ii in lipopolysaccharide-stimulated human coronary artery endothelial cells. Cardiovasc Drugs Ther 35:1083–1094. https://doi.org/10.1007/S10557-020-07083-W, DOI: 10.1007/S10557-020-07083-W</label>
          <listPosition>142</listPosition>
          <doi>10.1007/S10557-020-07083-W</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283436</mtid>
          <link>/api/reference/55283436</link>
          <label>143. Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:215–225. https://doi.org/10.1007/S00125-016-4157-3, DOI: 10.1007/S00125-016-4157-3</label>
          <listPosition>143</listPosition>
          <doi>10.1007/S00125-016-4157-3</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283437</mtid>
          <link>/api/reference/55283437</link>
          <label>144. Vaziri Z, Saleki K, Aram C, Alijanizadeh P, Pourahmad R, Azadmehr A, Ziaei N (2023) Empagliflozin treatment of cardiotoxicity: a comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomed Pharmacother 168:115686. https://doi.org/10.1016/J.BIOPHA.2023.115686, DOI: 10.1016/J.BIOPHA.2023.115686</label>
          <listPosition>144</listPosition>
          <doi>10.1016/J.BIOPHA.2023.115686</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283438</mtid>
          <link>/api/reference/55283438</link>
          <label>145. Vejpongsa P, Yeh ETH (2014) Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95:45–52. https://doi.org/10.1038/CLPT.2013.201, DOI: 10.1038/CLPT.2013.201</label>
          <listPosition>145</listPosition>
          <doi>10.1038/CLPT.2013.201</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283439</mtid>
          <link>/api/reference/55283439</link>
          <label>146. Villeneuve C, Guilbeau-Frugier C, Sicard P, Lairez O, Ordener C, Duparc T, De Paulis D, Couderc B, Spreux-Varoquaux O, Tortosa F, Garnier A, Knauf C, Valet P, Borchi E, Nediani C, Gharib A, Ovize M, Delisle MB, Parini A, Mialet-Perez J (2012) p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid Redox Signal 18:5–18. https://doi.org/10.1089/ARS.2011.4373, DOI: 10.1089/ARS.2011.4373</label>
          <listPosition>146</listPosition>
          <doi>10.1089/ARS.2011.4373</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283440</mtid>
          <link>/api/reference/55283440</link>
          <label>147. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011–1023. https://doi.org/10.1056/NEJMRA041809, DOI: 10.1056/NEJMRA041809</label>
          <listPosition>147</listPosition>
          <doi>10.1056/NEJMRA041809</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283441</mtid>
          <link>/api/reference/55283441</link>
          <label>148. Wright EM (2020) SGLT2 and cancer. Pflugers Arch 472:1407–1414. https://doi.org/10.1007/S00424-020-02448-4, DOI: 10.1007/S00424-020-02448-4</label>
          <listPosition>148</listPosition>
          <doi>10.1007/S00424-020-02448-4</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283442</mtid>
          <link>/api/reference/55283442</link>
          <label>149. Wu W, Zhang Z, Jing D, Huang X, Ren D, Shao Z, Zhang Z (2022) SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma. Cell Death Dis. https://doi.org/10.1038/S41419-022-04980-W, DOI: 10.1038/S41419-022-04980-W</label>
          <listPosition>149</listPosition>
          <doi>10.1038/S41419-022-04980-W</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283443</mtid>
          <link>/api/reference/55283443</link>
          <label>150. Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X (2019) Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J 17:661–674. https://doi.org/10.1016/J.CSBJ.2019.03.006, DOI: 10.1016/J.CSBJ.2019.03.006</label>
          <listPosition>150</listPosition>
          <doi>10.1016/J.CSBJ.2019.03.006</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283444</mtid>
          <link>/api/reference/55283444</link>
          <label>151. Xie Z, Wang F, Lin L, Duan S, Liu X, Li X, Li T, Xue M, Cheng Y, Ren H, Zhu Y (2020) An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells. Cancer Lett 495:200–210. https://doi.org/10.1016/J.CANLET.2020.09.005, DOI: 10.1016/J.CANLET.2020.09.005</label>
          <listPosition>151</listPosition>
          <doi>10.1016/J.CANLET.2020.09.005</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283445</mtid>
          <link>/api/reference/55283445</link>
          <label>152. Xu C, Wang W, Zhong J, Lei F, Xu N, Zhang Y, Xie W (2018) Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol 152:45–59. https://doi.org/10.1016/J.BCP.2018.03.013, DOI: 10.1016/J.BCP.2018.03.013</label>
          <listPosition>152</listPosition>
          <doi>10.1016/J.BCP.2018.03.013</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283446</mtid>
          <link>/api/reference/55283446</link>
          <label>153. Yamada T, Sakaguchi K, Okada Y, Miura H, Otowa-Suematsu N, So A, Komada H, Hirota Y, Ohara T, Kuroki Y, Hara K, Matsuda T, Kishi M, Takeda A, Yokota K, Tamori Y, Ogawa W (2021) Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation. Diabetol Int 12:197–206. https://doi.org/10.1007/S13340-020-00474-2/FIGURES/5, DOI: 10.1007/S13340-020-00474-2/FIGURES/5</label>
          <listPosition>153</listPosition>
          <doi>10.1007/S13340-020-00474-2/FIGURES/5</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283447</mtid>
          <link>/api/reference/55283447</link>
          <label>154. Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317–331. https://doi.org/10.1016/j.cell.2013.12.010, DOI: 10.1016/j.cell.2013.12.010</label>
          <listPosition>154</listPosition>
          <doi>10.1016/j.cell.2013.12.010</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283448</mtid>
          <link>/api/reference/55283448</link>
          <label>155. Yaribeygi H, Atkin SL, Butler AE, Sahebkar A (2019) Sodium–glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol 234:3231–3237. https://doi.org/10.1002/JCP.26760, DOI: 10.1002/JCP.26760</label>
          <listPosition>155</listPosition>
          <doi>10.1002/JCP.26760</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283449</mtid>
          <link>/api/reference/55283449</link>
          <label>156. Yaribeygi H, Maleki M, Nasimi F, Butler AE, Jamialahmadi T, Sahebkar A (2022) Sodium–glucose co-transporter 2 inhibitors and hematopoiesis. J Cell Physiol 237:3778–3787. https://doi.org/10.1002/JCP.30851, DOI: 10.1002/JCP.30851</label>
          <listPosition>156</listPosition>
          <doi>10.1002/JCP.30851</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283450</mtid>
          <link>/api/reference/55283450</link>
          <label>157. Ye J, Huang Y, Que B, Chang C, Liu W, Hu H, Liu L, Shi Y, Wang Y, Wang M, Zeng T, Zhen W, Xu Y, Shi L, Liu J, Jiang H, Ye D, Lin Y, Wan J, Ji Q (2018) Interleukin-12p35 knock out aggravates doxorubicin-induced cardiac injury and dysfunction by aggravating the inflammatory response, oxidative stress, apoptosis and autophagy in mice. EBioMedicine 35:29–39. https://doi.org/10.1016/J.EBIOM.2018.06.009, DOI: 10.1016/J.EBIOM.2018.06.009</label>
          <listPosition>157</listPosition>
          <doi>10.1016/J.EBIOM.2018.06.009</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283451</mtid>
          <link>/api/reference/55283451</link>
          <label>158. Ye J, Wang Y, Xu Y, Wang Z, Liu L, Wang M, Ye D, Zhang J, Yang Z, Lin Y, Ji Q, Wan J (2020) Interleukin-22 deficiency alleviates doxorubicin-induced oxidative stress and cardiac injury via the p38 MAPK/macrophage/Fizz3 axis in mice. Redox Biol 36:101636. https://doi.org/10.1016/J.REDOX.2020.101636, DOI: 10.1016/J.REDOX.2020.101636</label>
          <listPosition>158</listPosition>
          <doi>10.1016/J.REDOX.2020.101636</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283452</mtid>
          <link>/api/reference/55283452</link>
          <label>159. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St. Clair DK (1996) The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98:1253–1260. https://doi.org/10.1172/JCI118909, DOI: 10.1172/JCI118909</label>
          <listPosition>159</listPosition>
          <doi>10.1172/JCI118909</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283453</mtid>
          <link>/api/reference/55283453</link>
          <label>160. Yin J, Guo J, Zhang Q, Cui L, Zhang L, Zhang T, Zhao J, Li J, Middleton A, Carmichael PL, Peng S (2018) Doxorubicin-induced mitophagy and mitochondrial damage is associated with dysregulation of the PINK1/parkin pathway. Toxicol In Vitro 51:1–10. https://doi.org/10.1016/J.TIV.2018.05.001, DOI: 10.1016/J.TIV.2018.05.001</label>
          <listPosition>160</listPosition>
          <doi>10.1016/J.TIV.2018.05.001</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283454</mtid>
          <link>/api/reference/55283454</link>
          <label>161. Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD (2019) Sodium–glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 21:862–873. https://doi.org/10.1002/EJHF.1473, DOI: 10.1002/EJHF.1473</label>
          <listPosition>161</listPosition>
          <doi>10.1002/EJHF.1473</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283455</mtid>
          <link>/api/reference/55283455</link>
          <label>162. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. The Lancet 396:819–829. https://doi.org/10.1016/S0140-6736(20)31824-9, DOI: 10.1016/S0140-6736(20)31824-9</label>
          <listPosition>162</listPosition>
          <doi>10.1016/S0140-6736(20)31824-9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283456</mtid>
          <link>/api/reference/55283456</link>
          <label>163. Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD (2020) Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 141:1227–1234. https://doi.org/10.1161/CIRCULATIONAHA.119.044183, DOI: 10.1161/CIRCULATIONAHA.119.044183</label>
          <listPosition>163</listPosition>
          <doi>10.1161/CIRCULATIONAHA.119.044183</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283457</mtid>
          <link>/api/reference/55283457</link>
          <label>164. Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium–glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75:422–434. https://doi.org/10.1016/J.JACC.2019.11.031, DOI: 10.1016/J.JACC.2019.11.031</label>
          <listPosition>164</listPosition>
          <doi>10.1016/J.JACC.2019.11.031</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283458</mtid>
          <link>/api/reference/55283458</link>
          <label>165. Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A (2018) A sodium–glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 94:524–535. https://doi.org/10.1016/J.KINT.2018.05.002, DOI: 10.1016/J.KINT.2018.05.002</label>
          <listPosition>165</listPosition>
          <doi>10.1016/J.KINT.2018.05.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283459</mtid>
          <link>/api/reference/55283459</link>
          <label>166. Zhang Y, Zhang D, Meng T, Tian P, Chen J, Liu A, Zheng Y, Su G (2023) SGK1 is involved in doxorubicin-induced chronic cardiotoxicity and dysfunction through activation of the NFκB pathway. Int Immunopharmacol 125:111151. https://doi.org/10.1016/J.INTIMP.2023.111151, DOI: 10.1016/J.INTIMP.2023.111151</label>
          <listPosition>166</listPosition>
          <doi>10.1016/J.INTIMP.2023.111151</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283460</mtid>
          <link>/api/reference/55283460</link>
          <label>167. Zhao J, Zhang N, Ma X, Li M, Feng H (2023) The dual role of ferroptosis in anthracycline-based chemotherapy includes reducing resistance and increasing toxicity. Cell Death Discov 9:1–12. https://doi.org/10.1038/s41420-023-01483-1, DOI: 10.1038/s41420-023-01483-1</label>
          <listPosition>167</listPosition>
          <doi>10.1038/s41420-023-01483-1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283461</mtid>
          <link>/api/reference/55283461</link>
          <label>168. Zhao L, Yang Y, Gao Q (2019) Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: a case report. Immunotherapy 11:651–656. https://doi.org/10.2217/IMT-2018-0214, DOI: 10.2217/IMT-2018-0214</label>
          <listPosition>168</listPosition>
          <doi>10.2217/IMT-2018-0214</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283462</mtid>
          <link>/api/reference/55283462</link>
          <label>169. Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, Chen G, Liang Y, Zhang Q (2020) Sodium–glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. Biomed Pharmacother. https://doi.org/10.1016/J.BIOPHA.2020.110821, DOI: 10.1016/J.BIOPHA.2020.110821</label>
          <listPosition>169</listPosition>
          <doi>10.1016/J.BIOPHA.2020.110821</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283463</mtid>
          <link>/api/reference/55283463</link>
          <label>170. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720, DOI: 10.1056/NEJMoa1504720</label>
          <listPosition>170</listPosition>
          <doi>10.1056/NEJMoa1504720</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>55283464</mtid>
          <link>/api/reference/55283464</link>
          <label>171. Zullig LL, Sung AD, Khouri MG, Jazowski S, Shah NP, Sitlinger A, Blalock DV, Whitney C, Kikuchi R, Bosworth HB, Crowley MJ, Goldstein KM, Klem I, Oeffinger KC, Dent S (2022) Cardiometabolic comorbidities in cancer survivors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 4:149–165. https://doi.org/10.1016/J.JACCAO.2022.03.005, DOI: 10.1016/J.JACCAO.2022.03.005</label>
          <listPosition>171</listPosition>
          <doi>10.1016/J.JACCAO.2022.03.005</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
      </references>
      <link>/api/publication/35077353</link>
      <label>Camilli Massimiliano et al. Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. (2025) BASIC RESEARCH IN CARDIOLOGY 0300-8428 1435-1803 120 241-262</label><template>&lt;div class=&quot;JournalArticle Publication short-list&quot;&gt; &lt;div class=&quot;authors&quot;&gt; &lt;span class=&quot;author-name&quot; &gt; Camilli, Massimiliano ✉ &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Viscovo, Marcello&lt;sup&gt;*&lt;/sup&gt; &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Maggio, Luca&lt;sup&gt;*&lt;/sup&gt; &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Bonanni, Alice &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Torre, Ilaria &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Pellegrino, Claudio &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Lamendola, Priscilla &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Tinti, Lorenzo &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Teofili, Luciana &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; &gt; Hohaus, Stefan &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; et al. &lt;/div &gt;&lt;div class=&quot;title&quot;&gt;&lt;a href=&quot;/gui2/?mode=browse&amp;params=publication;35077353&quot; mtid=&quot;35077353&quot; target=&quot;_blank&quot;&gt;Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond&lt;/a&gt;&lt;/div&gt; &lt;div class=&quot;pub-info&quot;&gt; &lt;span class=&quot;journal-title&quot;&gt;BASIC RESEARCH IN CARDIOLOGY&lt;/span&gt; &lt;span class=&quot;journal-volume&quot;&gt;120&lt;/span&gt; &lt;span class=&quot;page&quot;&gt; pp. 241-262. , 22 p. &lt;/span&gt; &lt;span class=&quot;year&quot;&gt;(2025)&lt;/span&gt; &lt;/div&gt; &lt;div class=&quot;pub-end&quot;&gt;&lt;div class=&quot;identifier-list&quot;&gt; &lt;span class=&quot;identifiers&quot;&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;10.1007/s00395-024-01059-9&quot; target=&quot;_blank&quot; href=&quot;https://doi.org/10.1007/s00395-024-01059-9&quot;&gt; DOI &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;001256980900001&quot; target=&quot;_blank&quot; href=&quot;https://www.webofscience.com/wos/woscc/full-record/001256980900001&quot;&gt; WoS &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;85197457276&quot; target=&quot;_blank&quot; href=&quot;http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85197457276&quot;&gt; Scopus &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;38935171&quot; target=&quot;_blank&quot; href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=38935171&amp;dopt=Abstract&quot;&gt; PubMed &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;https://link.springer.com/10.1007/s00395-024-01059-9&quot; target=&quot;_blank&quot; href=&quot;https://link.springer.com/10.1007/s00395-024-01059-9&quot;&gt; Egyéb URL &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_NONE&quot; title=&quot; Nincs &quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;https://www.scopus.com/pages/publications/85197457276?origin=resultslist&quot; target=&quot;_blank&quot; href=&quot;https://www.scopus.com/pages/publications/85197457276?origin=resultslist&quot;&gt; Egyéb URL &lt;/a&gt; &lt;/span&gt; &lt;/span&gt; &lt;/div&gt; &lt;div class=&quot;short-pub-prop-list&quot;&gt; &lt;span class=&quot;deleted-record&quot;&gt;Központi kezelésű&lt;/span&gt; &lt;span class=&quot;short-pub-mtid&quot;&gt; Közlemény:35077353 &lt;/span&gt; &lt;span class=&quot;status-holder&quot;&gt;&lt;span class=&quot;status-data status-VALIDATED&quot;&gt; Egyeztetett &lt;/span&gt;&lt;/span&gt; &lt;span class=&quot;pub-core&quot;&gt;Forrás Idéző &lt;/span&gt; &lt;span class=&quot;pub-type&quot;&gt;Folyóiratcikk (Összefoglaló cikk ) &lt;/span&gt; &lt;!-- &amp;&amp; !record.category.scientific --&gt; &lt;span class=&quot;pub-category&quot;&gt;Tudományos&lt;/span&gt; &lt;div class=&quot;publication-citation&quot; style=&quot;margin-left: 0.5cm;&quot;&gt; &lt;span title=&quot;Nyilvános idézőközlemények összesen, említések nélkül&quot; class=&quot;citingPub-count&quot;&gt;Nyilvános idéző összesen: 19&lt;/span&gt; | Független: 13 | Függő: 6 | Nem jelölt: 0 | WoS jelölt: 18 | Scopus jelölt:&amp;nbsp;15 | WoS/Scopus jelölt:&amp;nbsp;19 | DOI jelölt:&amp;nbsp;19 &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;</template><template2>&lt;div class=&quot;JournalArticle Publication long-list&quot;&gt;
&lt;div class=&quot;authors&quot;&gt;
	&lt;img title=&quot;Forrásközlemény&quot; style=&quot;float: left&quot; src=&quot;/frontend/resources/grid/publication-core-icon.png&quot;&gt;
	&lt;img title=&quot;Idézőközlemény&quot; style=&quot;float: left&quot; src=&quot;/frontend/resources/grid/publication-citation-icon.png&quot;&gt;

		&lt;div class=&quot;autype autype0&quot;&gt;				&lt;span class=&quot;author-name&quot; &gt;Camilli Massimiliano ✉
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Viscovo Marcello&lt;sup&gt;*&lt;/sup&gt;
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Maggio Luca&lt;sup&gt;*&lt;/sup&gt;
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Bonanni Alice
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Torre Ilaria
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Pellegrino Claudio
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Lamendola Priscilla
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Tinti Lorenzo
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Teofili Luciana
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Hohaus Stefan
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Lanza Gaetano Antonio
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; mtid=&quot;10010125&quot;&gt;&lt;a 
																				   href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10010125&quot; target=&quot;_blank&quot;&gt;Ferdinandy Peter
            (&lt;span class=&quot;authorship-author-name&quot;&gt;Ferdinandy Péter&lt;/span&gt;
            &lt;span class=&quot;authorAux-mtmt&quot;&gt; Farmakológia, molekuláris medicina&lt;/span&gt;)
			&lt;/a&gt;
    &lt;/span&gt;
&lt;span class=&quot;author-affil&quot;&gt;&lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Intézet&quot;&gt;I&lt;/span&gt;/Farmakológiai és Farmakoterápiás Intézet; &lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Intézet&quot;&gt;I&lt;/span&gt;/&lt;span title=&quot;Farmakológiai és Farmakoterápiás Intézet&quot;&gt;FFI&lt;/span&gt;/MTA-SE Rendszerfarmakológiai Kutatócsoport&lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; mtid=&quot;10028393&quot;&gt;&lt;a 
																				   href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10028393&quot; target=&quot;_blank&quot;&gt;Varga Zoltan
            (&lt;span class=&quot;authorship-author-name&quot;&gt;Varga Zoltán&lt;/span&gt;
            &lt;span class=&quot;authorAux-mtmt&quot;&gt; kardiovaszkuláris kutatás&lt;/span&gt;)
			&lt;/a&gt;
    &lt;/span&gt;
&lt;span class=&quot;author-affil&quot;&gt;&lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Intézet&quot;&gt;I&lt;/span&gt;/Farmakológiai és Farmakoterápiás Intézet; &lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Intézet&quot;&gt;I&lt;/span&gt;/&lt;span title=&quot;Farmakológiai és Farmakoterápiás Intézet&quot;&gt;FFI&lt;/span&gt;/HCEMM-SE Kardiometabolikus Immunológia Kutatócsoport; &lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Intézet&quot;&gt;I&lt;/span&gt;/&lt;span title=&quot;Farmakológiai és Farmakoterápiás Intézet&quot;&gt;FFI&lt;/span&gt;/MTA-SE Momentum Kardio-Onkológia és Kardioimmunológia Kutatócsoport&lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Crea Filippo
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Lombardo Antonella
    &lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; &gt;Minotti Giorgio
    &lt;/span&gt;

				    &lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;title&quot;&gt;&lt;a href=&quot;/gui2/?mode=browse&amp;params=publication;35077353&quot; target=&quot;_blank&quot;&gt;Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond&lt;/a&gt;&lt;/div&gt;    &lt;div&gt;		&lt;span class=&quot;journal-title&quot;&gt;BASIC RESEARCH IN CARDIOLOGY&lt;/span&gt;

        &lt;span class=&quot;journal-issn&quot;&gt;(&lt;a target=&quot;_blank&quot; href=&quot;https://portal.issn.org/resource/ISSN/0300-8428&quot;&gt;0300-8428&lt;/a&gt; &lt;a target=&quot;_blank&quot; href=&quot;https://portal.issn.org/resource/ISSN/1435-1803&quot;&gt;1435-1803&lt;/a&gt;)&lt;/span&gt;:
		&lt;span class=&quot;journal-volume&quot;&gt;120&lt;/span&gt; 
&lt;span class=&quot;page&quot;&gt;
	pp 241-262
			
&lt;/span&gt;		 &lt;span class=&quot;year&quot;&gt;(2025)&lt;/span&gt;  
    &lt;/div&gt;
&lt;div class=&quot;pub-footer&quot;&gt;
    

	&lt;span class=&quot;language&quot; xmlns=&quot;http://www.w3.org/1999/html&quot;&gt;Nyelv:
			Angol
		 |  &lt;/span&gt;

	&lt;span class=&quot;identifiers&quot;&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;10.1007/s00395-024-01059-9&quot; target=&quot;_blank&quot; href=&quot;https://doi.org/10.1007/s00395-024-01059-9&quot;&gt;
									DOI
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;001256980900001&quot; target=&quot;_blank&quot; href=&quot;https://www.webofscience.com/wos/woscc/full-record/001256980900001&quot;&gt;
									WoS
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;85197457276&quot; target=&quot;_blank&quot; href=&quot;http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85197457276&quot;&gt;
									Scopus
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;38935171&quot; target=&quot;_blank&quot; href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=38935171&amp;dopt=Abstract&quot;&gt;
									PubMed
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;https://link.springer.com/10.1007/s00395-024-01059-9&quot; target=&quot;_blank&quot; href=&quot;https://link.springer.com/10.1007/s00395-024-01059-9&quot;&gt;
									Egyéb URL
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_NONE&quot; title=&quot;	Nincs
&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;https://www.scopus.com/pages/publications/85197457276?origin=resultslist&quot; target=&quot;_blank&quot; href=&quot;https://www.scopus.com/pages/publications/85197457276?origin=resultslist&quot;&gt;
									Egyéb URL
							&lt;/a&gt;
						&lt;/span&gt;
	&lt;/span&gt;


	&lt;OnlyViewableByAuthor&gt;&lt;div class=&quot;ratings&quot;&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Cardiology and Cardiovascular Medicine&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;D1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Physiology (medical)&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;D1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Physiology&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;D1&lt;/div&gt;
    &lt;/div&gt;&lt;/OnlyViewableByAuthor&gt;


	&lt;div class=&quot;publication-citation&quot; style=&quot;margin-left: 0.5cm;&quot;&gt;
		&lt;span title=&quot;Nyilvános idézőközlemények összesen, említések nélkül&quot; class=&quot;citingPub-count&quot;&gt;Nyilvános idéző összesen: 19&lt;/span&gt;
		| Független: 13
		| Függő: 6
		| Nem jelölt: 0
		| WoS jelölt: 18 
		|  Scopus jelölt:&amp;nbsp;15 
		|  WoS/Scopus jelölt:&amp;nbsp;19 
		|  DOI jelölt:&amp;nbsp;19 
		
	&lt;/div&gt;
    
    
	&lt;div class=&quot;publication-citation&quot;&gt;
		&lt;a target=&quot;_blank&quot; href=&quot;/api/publication?cond=citations.related;eq;35077353&amp;sort=publishedYear,desc&amp;sort=title&quot;&gt;
			Idézett közlemények száma: 14
		&lt;/a&gt;
	&lt;/div&gt;



    &lt;div class=&quot;mtid&quot;&gt;&lt;span class=&quot;long-pub-mtid&quot;&gt;Közlemény: 35077353&lt;/span&gt;
    | &lt;span class=&quot;status-data status-VALIDATED&quot;&gt; 	Egyeztetett
  &lt;/span&gt;
        
	
	
Forrás	 Idéző
	
	
    | &lt;span class=&quot;type-subtype&quot;&gt;Folyóiratcikk
			( Összefoglaló cikk
			
			)
		&lt;/span&gt;
      		| &lt;span class=&quot;pub-category&quot;&gt;Tudományos&lt;/span&gt;
	| &lt;span class=&quot;publication-sourceOfData&quot;&gt;kézi felvitel&lt;/span&gt;
&lt;/div&gt;


&lt;div class=&quot;lastModified&quot;&gt;Utolsó módosítás: 2026.06.09. 19:46 Molnár-Taga Márta (SE 4-es admin)
&lt;/div&gt;


        &lt;div class=&quot;lockedBy&quot;&gt;Központi kezelésű 2026.06.09. 20:51  Lévayné Deseő Katalin (MTMT Központi admin)
        &lt;/div&gt;


	&lt;pre class=&quot;comment&quot; style=&quot;margin-top: 0; margin-bottom: 0;&quot;&gt;&lt;u&gt;Megjegyzés&lt;/u&gt;: Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy            
            Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli, 1, Rome, 00168, Italy            
            Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cu...&lt;/pre&gt;

&lt;/div&gt;&lt;/div&gt;</template2>
    </publication>
  </content>
</myciteResult>
